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THE EFFECTS OF CTDSP1 ON TOPOI DEGRADATION AND CELLULAR 
RESISTANCE TO TOPOI INHIBITOR CHEMOTHERAPY TREATMENT 
EMMA SWAYZE 
ABSTRACT 
 The anticancer drug Camptothecin (CPT) specifically targets topoisomerase I 
(topoI). While this class of drug is used to treat various solid tumors, CPT is only 
effective in 13-30 percent of the patient population. Although the mechanism of the CPT 
resistance pathway is not fully understood, we found cancer cells degrade topoisomerase 
I (topoI) in response to CPT. The observed relationship between higher basal DNA-PKcs 
mediated phosphorylation of topoI, rapid degradation of topoI, and resistance to CPT 
suggested that DNA-PKcs is a critical regulator of the phosphorylation status of topoI 
and the rate of topoI degradation in response to CPT. The data shows CTDSP1 (a dual 
phosphatase) acts as a negative regulator of DNA-PKcs. Because CTDSP1 functionality 
plays a role in maintaining higher basal phosphorylation levels of topoI, CTDSP1 
impairment contributes to greater CPT resistance. This renders the CPT chemotherapy 
treatment ineffective. We hypothesized inducing the catalytically inactive form of 
CTDPS1 via both knockdown and inhibition experiments would increase cancer cell 
resistance to CPT as a result of an overactive topoI degradation pathway.  The function of 
CTDSP1 was impaired in the two colon cancer cell lines, HCT15 and HCT116, by 
silencing with siRNA and using Rabeprazole (a pharmacological agent known to inhibit 
CTDSP1). Inhibition of CTDSP1 phosphatase activity resulted in greater phosphorylation 
of DNA-PKcs and increased the rate of topoI degradation in the cells in response to CPT. 
		 vii 
Cellular resistance was also more notable in the sensitive HCT116 cell lines. HCT15 cells 
degrade topoI rapidly and are resistant to CPT. Thus, the effect of CPT is not as 
pronounced in this cell line. CTDSP1 knock down cells showed the greatest DNA-PKcs 
phosphorylation and topoI degradation when treated with CPT.   In addition, the present 
study includes a clonogenic assay that shows a larger cell survival fraction in 
Rabeprazole treated HCT116 cells in comparison to controls after exposure to CPT. A 
higher survival fraction after CPT exposure is reflective of greater CPT resistance. This 
suggests that cell viability is enhanced during CPT chemotherapy treatment in CTDSP1 
null colorectal cancer cells. Lastly, An EGFP read out experiment of topoI tagged to 
EGFP demonstrated CTDSP1 inhibition results in reduced topoI levels in colorectal 
cancer cells. The present study showed the potential link between lower topoI levels and 
greater resistance to CPT by showing that both effects are outcomes of silencing 
CTDSP1.  
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INTRODUCTION 
 
TopoI 
 
Human DNA topoisomerase I (topoI) is located on chromosome 20q 11.2-13.1 
and its primary function is to relieve DNA supercoiling during DNA replication and 
transcription (Fujimori et al. 1996). To manage the torsion caused by an advancing 
replication fork, topo I temporarily forms a covalent bond at the 3’ terminus of DNA and 
produces a single strand break (Fujimori et al. 1996). The 5’ end of DNA rotates freely 
and chaperones strand relaxation until topoI catalyzes religation of the strand. The topoI 
dissociates from the DNA at the end of the process (Fujimori et al.1996).  TopoI plays a 
critical role in replication and transcription, but more importantly, has been identified as a 
specific target for a class of neoplastic drugs, Camptothecin (CPT) and its analogues. 
This class of drug is used to treat various solid tumors including colorectal cancer (CRC), 
small cell lung cancer (SCLC), pancreatic, and ovarian cancer. 
Colorectal Cancer Chemotherapy 
 The most common therapies listed in the National Comprehensive Cancer 
Network (NCCN) guideline include Oxialiplatin based and Irenotecan based treatments 
for CRC (Ando et al. 2017). According to the CALGB/SWOG 80405 trial, the 
Oxialiplatin treatments are preferable in the United States. However, Irenotecan, a 
Camptothecin analogue, based treatments have the potential to be extremely successful in 
a subset of patients. For example, a case study in Japan evaluated a 49-year-old male 
demonstrating an 11.8cm, or 52%, tumor reduction after an Irenotecan based therapy 
(Ando et al. 2017). In order to ensure patients are receiving the best care possible, it is 
	2 
necessary to determine a biomarker to establish whether patients will or will not respond 
to Irenotecan. Production of a biomarker will allow certain patients the opportunity to try 
this alternative treatment that may be vastly more successful than the Oxialiplatin 
treatment. Additionally, establishing a biomarker will allow physicians to avoid 
administering this alternative treatment to patients with resistant cells. In order to 
discover factors indicative of cellular resistance, it is essential to explore the mechanism 
of Camptothecin.  
Camptothecin Mechanisms 
The mechanisms of topoI inhibition by CPTs are well understood.  CPTs block 
the DNA-re-ligation step of the topoI mediated DNA cutting and re-ligation cycle 
(Goldwasser et al. 1995). CPT induces cytotoxicity through binding and stabilizing DNA 
and topoI to form a cleavable complex (Hsiang et al. 1988).  The resulting collisions with 
the replication fork leads to a DNA-double strand break and cell death (Liu et al. 2000). 
The effectiveness of CPT was tested on a variety of cell lineages and showed varying 
effectiveness.  While some patients responded well to CPT treatment, others 
demonstrated resistance to the CPT drug. The response rate to CPT was only 30% in a 
trial conducted on patients with CRC (Arakawa et al. 2006). The ineffectiveness of CPT 
on certain cell lines led to an investigation of potential mechanisms of drug resistance.  
Potential Mechanisms for Resistance 
Many studies evaluated the possibility of a mutation of the topoI gene as the 
mechanism for CPT drug resistance. In an in vitro study, a CPT resistant sub-line of 
colon cancer cells DLDSNR6 was compared to CPT non-resistant DLD-1 colon cancer 
	3 
cells (Arakawa et al.2006). It was determined that the resistant cells possessed a topoI 
gene mutation where glycine was substituted for serine at amino acid residue 365 
(G365S) (Arakawa et al. 2006). While the mutation had no effect on the amount of topoI 
present in the cell, there was a notable decrease in catalytic ability of the mutated topoI.  
When treated with CPT, mutated cells produced less topoI and DNA cleavable 
complexes compared to non-mutated DLD-1 cells (Arakawa et al.2006).  This 
experiment suggests that the mutation prevented topoI from producing a stable complex 
with DNA, which contributes to CPT resistance. Additionally, in vitro studies were 
conducted with CPT derivatives in SN-38 resistant human colon cancer cells.  Results 
indicated that a G365S mutation hindered the ability of CPT analogues to interact with 
topoI at the 3’ catalytic tyrosine (Arakawa et al. 2006).  Although in vitro studies showed 
promising results for the connection between genetic mutations and CPT resistance, 
clinical trials showed no significant results for the relationship. Another experiment that 
investigated the clinical relevance of topoI mutations to CPT resistance was conducted on 
127 samples from 56 patients with lung tumors (Ohashi et al.1996). In vitro point 
mutations that were thought to be a mechanism of CPT resistance showed no significant 
difference in CPT resistance in vivo. While topoI gene mutations may alter CPT binding 
and cause some resistance, it is not considered to be the main mechanism. Finally, data 
from an antidrug screen for 60 human tumor cell lines conducted by National Cancer 
Institute revealed no correlation between gene expression profiles and CPT drug (Scherf 
et al.2000).  
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Another avenue explored for the mechanism of CPT resistance was removal of 
CPT via ABC transporter. Researchers used Rhodamine as a predictive measure of anti-
cancer drug response to ABC transporter expression (Lee et al.1994). Results showed 
ABC-B1 removes chemotherapeutic agents from cells, causing resistance to the drugs.  
The NCI used a PCR of cDNA to evaluate the mRNA expression of 48 human ABC 
transporters in 60 cancer cell lines. These cell lines were then screened for a correlation 
between ABC transporter gene expression and CPT response, and the results are shown 
in Figure 1 (Szakacs et al.2004).  ABC-B1 transporters could potentially promote drug 
resistance if the transporters removed CPT from the cell. If CPT resistance were related 
to ABC transporter protein expression, low level of CPT inside the cell would be 
expected in the presence of transporter. The results in Figure 1 reveal CPT is not a 
substrate for ABC transporters including ABCB1 (Szakacs et al.2004). This suggests 
there is no relationship between CPT resistance and ABC-B1 expression, and thus no 
relationship between CPT and ABC transporters. 
Figure 1: Adapted from the Szakacs study, Figure 1 
shows the effect of ABC-B1 transporter expression 
on drug sensitivity in 60 cancer cell lines. Blue bars 
indicate low expression of drug in the presence of 
the ABC-B1 transporter. These drugs are substrates 
of the ABC-B1 transporter. In contrast, agents 
characterized by red bars, like CPT, are not 
substrates of the ABC-B1 transporter and are highly 
expressed inside the cell in the presence of the ABC-
B1 transporter.  High expression of CPT inside the 
cell in the presence of the transporter suggests CPT 
resistance is largely due to another mechanism.  
 
A more recent alternative mechanism of resistance that has been suggested 
involves the rate of degradation of topoI through the ubiquitin 26S proteasome pathway 
	5 
(Desai et al.2001). Studies were conducted on CPT sensitive ZR-75-1 and CPT resistant 
BT474 breast cancer cell lines (Desai et al. 2001). ZR-75-1 cells defective in topoI down 
regulation were the most sensitive to CPT and experienced apoptosis, whereas BT474 
cells with the ability to effectively down regulate topoI were most resistance to CPT 
(Desai et al. 2001). These results suggest a relationship between CPT-induced down 
regulation of topoI and CPT resistance.   
To further examine the mechanism of topoI down regulation on CPT resistance, a 
26S proteasome inhibitor MG132 was used to inhibit topoI degradation in BT474 and 
V79 cell lines (Desai et al.2001). In the presence of MG132, both cell lineages 
experienced increased cytotoxicity from CPT and greater efficacy of the anti-cancer drug. 
In addition, the Bharti lab treated both sensitive HCT116 and resistant HCT15 cell lines 
containing topoI tagged to EGFP with SN-38, a form of CPT (Ando et al. 2017). The 
intensity of EGFP fluorescence was recorded at different time intervals in order to 
measure the degradation of topoI (Ando et al. 2017). Immunofluorescent staining shown 
in Figure 2 reveals the intensity of EGFP decreases after SN-38 treatment.  
 Figure 2: Adapted from the Ando study, 
Figure 2 reveals live imaging of topoI-
EGFP in resistant cell line HCT15 with 
and without treatment of SN-38 (Ando et 
al. 2017). Greater intensity located near 
the nucleolus region of the cell represents 
topoI tagged to EGFP within the cell. 
Panel A, containing HCT15 cells without 
SN-38 exposure, shows greater intensity 
than HCT15 cells treated with 2.5µM SN-
38 in Panel B. Greater degradation of 
topoI is observed in HCT15 cells after 
treatment with SN-38. 
 
B	
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These results indicate treatment with SN-38 triggers the topoI degradation 
pathway. The more CPT resistant HCT15 cell line degrades topoI faster than the sensitive 
HCT116 cell line, suggesting the role of topoI degradation as a contributor to CPT 
resistance. Evaluating the intensity of EGFP immunofluorescence is a method of 
measuring the quantity of the EGFP tagged topoI in a cell that I will use in my 
experiments.  
The link between topoI degradation and cellular resistance to CPT chemotherapy 
treatment has inspired researchers to examine the topoI degradation pathway shown in 
detail in Figure 3 (Ando et al. 2017). The rate of topoI degradation in the cell influences 
the cellular response to CPT. When topoI is degraded faster, CPT is less effective at 
destroying cells. An immunohistochemistry (IHC) experiment conducted in the Bharti lab 
revealed that a larger quantity of topoI is phosphorylated at serine 10 in CPT resistant 
colorectal cancer cells than in sensitive cell lines (Ando et al. 2017). This suggests that 
phosphorylation of topoI is a critical step in degradation.  
Higher basal levels of serine 10 topoI phosphorylation were observed in cells 
demonstrating greater resistance to CPT. This relationship led the Bharti lab to 
investigate upstream events contributing to these resistance conditions. The Bharti lab 
silenced a myriad of phosphatases in order to isolate proteins influencing DNA-PKcs. 
After further examination of the topoI degradation pathway, CTDSP1 and PTEN were 
identified as upstream candidates influencing the phosphorylation and activation of 
DNA-PKcs.  When silenced CTDSP1 and PTEN were unable to remove the phosphate 
from DNA-PKcs (Ando et al. 2017). Phosphorylation of DNA-PKcs activates the kinase 
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to phosphorylate other proteins including topoI. Post phosphorylation, topoI is 
ubiquitinated and subsequently degraded.  
 
Figure 3: Adapted from the Bharti lab, Figure 3 shows the degradation pathway of topoI (Ando 
et al. 2017). When phosphorylated, DNA-PKcs is activated to phosphorylate topoI. BRAC1 
interacts with and ubiquitinates phosphorylated topoI, initiating the proteolytic degradation 
pathway. When topoI is degraded by the proteasome, CPT has no substrate to interact with and is 
no longer an effective therapeutic agent.  
 
Silencing of phosphatases PTEN and CTDSP1 shows both proteins also play a 
role in topoI degradation. The Bharti lab administered an siRNA library screening to 
nuclear phosphatases where 56 nuclear phosphatase genes were silenced by siRNA and 
then treated with SN-38 (Ando et al. 2017). EGFP tagged topoisomerase was then 
measured at various time intervals. Figure 4 demonstrates the differences in 
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immunofluorescent staining with anti-topoI-antibody between cells under control 
conditions and after knockdown of PTEN. Cells with PTEN knocked down demonstrated 
less immunofluorescence, indicating greater topoI degradation in the CPT treated cells 
(Ando et al. 2017).  
 
 
 
Figure 4: Adapted from the Bharti lab, Figure 4A shows immunofluorescent staining of cells 
with PTEN compared to PTEN knock out cells after exposure to SN-38 for different time 
intervals (Ando et al. 2017). Greater immunofluorescence reflects a greater amount of topoI in the 
cell. Less intensity is notable in PTEN knockout cells treated with SN-38 for both 90 and 180 
minutes. Figure 4B shows the measurement of topoI immunofluorescence intensity using ImageJ 
software. Because intensity levels reached the lowest point in PTEN knockout cells exposed to 
SN-38 for 180 minutes, topoI degradation was the greatest in these cells relative to the control.  
 
Knocking out PTEN not only enhances breakdown of topoI, but also increases 
cellular resistance to CPT. After plated cells with both functional and knocked down 
PTEN were treated with SN-38 for 24 hours, the cells without PTEN exhibited greater 
proliferation (Ando et al. 2017). The Bharti lab further explored the mechanism of PTEN 
in the topoI degradation pathway in order to understand how the protein confers cellular 
resistance to SN-38. A DNA-PKcs kinase assay revealed that DNA-PKcs is 
A	
B	
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dephosphorylated by PTEN (Ando et al. 2017). When PTEN is non-functional, there is 
greater phosphorylation of DNA-PKcs, which leads to greater topoI phosphorylation and 
then degradation. Figure 5 shows the influence of PTEN on the topoI degradation 
pathway (Ando et al. 2017). Because PTEN knockdown cells are more resistant to SN-
38, greater phosphorylation of DNA-PKcs may be another indicator of cellular resistance 
to CPT. Factors such as greater DNA-PKcs phosphorylation, lower levels of topoI, and 
non-functional PTEN serve as predictive biomarkers for cellular resistance to CPT 
colorectal cancer chemotherapy treatment. Phosphorylation of topoI by pDNA-PKcs 
marks topoI for ubiquitination followed by degradation, making cells resistant to CPT. In 
my experiment, I will be looking at the phosphatase CTDSP1 identified in the siRNA 
screening to determine whether CTDSP1 influences cellular resistance to CPT in a 
similar manner to PTEN. The Bharti lab generated an antibody against topoI phospho-
S10 that will be used in my IHC experiment to examine the levels of topoI after knocking 
out CTDSP1 (Ando et al. 2017). 
Figure 5: Adapted from the Bharti lab, Figure 5 
shows the role of PTEN in the topoI degradation 
pathway (Ando et al. 2017).  When PTEN is not 
present in the cell, DNA-PKcs remains 
phosphorylated and is able to phosphorylate 
topoI. Phosphorylation of topoI recruits BRCA1 
and associated proteins that ubquitinate and 
initiate topoI degradation. CTDSP1 is 
hypothesized to perform a similar function to 
that of PTEN and may also influence the topoI 
degradation pathway leading to cellular 
resistance to CPT.  
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CTDSP1 and CPT Resistance 
CTDSP1 plays a similar role to the phosphatase PTEN.  The phosphatase PTEN is 
known to remove the phosphate from DNA-PKcs, which is then activated to 
phosphorylate topoI, leading to the subsequent degradation of topoI.  CTDSP1 is a 
serine/threonine phosphatase that is part of the SCP protein family (Lin et al. 2014). 
Proteins belonging to the SCP family dephosphorylate at the C terminal domain of 
proteins (Lin et al. 2014). Additionally, loss of function of these phosphatases has 
demonstrated an increase in tumor formation and proliferation for several types of 
cancers including clear cell renal cell carcinoma (Kashuba et al. 2004). The Lin study 
demonstrated overexpression of CTDSP1 in ccRCC cell lines 786-O and A-498 (Lin et 
al. 2014).  
CTDSP1 has also been shown to regulate the stability of the transcription factor c-
Myc. Enhanced expression of c-Myc is correlated with tumorigenesis (Wang et al. 2015). 
Similar to topoI, c-Myc stability is also regulated by phosphorylation.  CTDSP1 inhibits 
c-Myc mediated phosphorylation via dephosphorylating a serine 62 residue (Wang et al. 
2015). Figure 6 demonstrates that wild-type CTDSP1 reduces c-Myc phosphorylation at 
Ser62, whereas a catalytically inactive mutant of CTDSP1 does not influence c-Myc 
phosphorylation (Wang et al. 2015). This suggests that CTDSP1 is responsible for direct 
dephosphorylation at the Ser62 residue on c-Myc.   
 
Figure 6: Adapted from the W. Wang study, figure 6 shows that 
in the presence of catalytically active wild type GST-SCP1 (also 
referred to as CTDSP1) the serine 62 residue of c-Myc does not 
undergo phosphorylation. The DN non-catalytically active 
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version of GST-SCP1 does result in phosphorylation of c-Myc. This suggests that the presence 
alone of GST-SCP1 is not enough to remove the phosphate from c-Myc. Catalytic activation of 
GST-SCP1 is essential for dephosphorylation effects to occur.  
 
The Wang study examines the levels of c-Myc in the presence of both CTDSP1-
WT and the inactive CTDSP1 mutant using a western blot. Results indicate CTDSP1 is a 
negative regulator of c-Myc, for in the presence of the wild type CTDSP1, levels of c-
Myc protein are reduced. In my experiment, I use the western blotting technique to assess 
the amount of various proteins after both inhibiting CTDSP1 with Rabeprazole and 
knocking down CTDSP1 with siRNA. To explore the physical interaction between 
CTDSP1 and the substrate c-Myc, a pull down assay using glutathione S- transferase was 
conducted. Results revealed that both wild type and catalytically inactive mutant 
CTDSP1 directly interacted with c-Myc (Wang et al. 2015). Therefore, the direct 
interaction between the two proteins occurs regardless of the phosphatase activity (Wang 
et al. 2015). 
The previous experiments suggest the role of CTDSP1 as a phosphatase that 
regulates proteins involved in the topoisomerase degradation pathway at a serine residue 
located near the C-terminal domain. Before knocking down CTDSP1 using siRNA, 
experiments were conducted using an inhibitor of CTDSP1. Inhibitors of phosphatases 
from the Scp family like CTDSP1 were screened in a pilot library of the NIH clinical 
collection and spectrum collection to assess for ability to inhibit CTDSP1 specifically. 
Results indicated Rabeprazole would serve as an inhibitor for CTDSP1 (Zhang et al. 
2011). To better understand the interaction between Rabeprazole and CTDSP1, X ray 
data collection was conducted in the Zhang study on Scp1 crystals (PEG-based 
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conditions) soaked in 0.5mM Rabeprazole for 2-3 hours (Zhang et al. 2011). Figure 7 
reveals maximum interaction between the hydrophobic recognition pocket of CTDSP1 
and the Pro3 residue of Rabeprazole (Zhang et al. 2011).  
 
Figure 7: Adapted from the Zhang 
study, Figure 7 shows a 3D model 
of the interaction between the Pro3 
residue of Rabeprazole and the 
hydrophobic binding pocket of 
Scp1.  
 
 
 
 
A mutagenesis experiment around the hydrophobic binding pocket examined the 
ability of Rabeprazole to inhibit CTDSP1 when the hydrophobic binding pocket was 
altered (Zhang et al. 2011). Results suggest that when the hydrophobic binding pocket of 
CTDSP1 is mutated, the ability of Rabeprazole to inhibit the phosphatase is decreased, 
suggesting the hydrophobic binding pocket is critical for the interaction of the two 
molecules.  
In current medical practice, Rabeprazole has been used to treat peptic ulcers and 
GERD by targeting and irreversibly inhibiting proton exchange via the hydrogen 
potassium ATPase (Gu et al. 2014).  While the mechanism for proton pump inhibition is 
through a covalent bond, Rabeprazole non-covalently binds Pro3 of the CTD peptide in 
the hydrophobic binding pocket of CTDSP1 (Zhang et al. 2011). Additionally, when 
treated with Rabeprazole, gastric cancer cells experienced reduced viability. Typically, 
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gastric cancer cells have an extremely active proton pump and ability to eradicate protons 
within the cell. Rabeprazole inhibits the pump in gastric cancer cells, which creates an 
extremely acidic environment within the cancer cell that leads to cell death (Gu et al. 
2014). The Gu study also shows Rabeprazole inhibits the phosphorylation of ERK1/2 
(Gu et al. 2014).  Without phosphorylation of ERK1/2, the signal transduction pathway 
that ERK1/2 initiates was suppressed, leading to induction of apoptosis in gastric cancer 
cells (Gu et al. 2014). ERK phosphorylation leads to degradation of repressor element 
silencing transcription factor (REST), a compound that stunts neurogenesis (Nesti et al. 
2014). Therefore CTDSP1 is responsible for stabilizing REST and preventing growth and 
differentiation from occurring. In addition, preventing phosphorylation at S861/864 
residues located near the C terminus of the REST led to increased stability of REST 
(Nesti et al. 2014).   ERK1 and 2 are kinases responsible for phosphorylation of REST at 
S861/864 residues that enhance growth. Based on the results of these experiments, it is 
possible CTDSP1 may influence DNA-PKcs in a similar manner to REST. Normal 
CTDSP1 may prevent proline-directed phosphorylation at C terminal serine residues of 
DNA-PKcs. In my experiments, I will both knock down CTDSP1 with siRNA and inhibit 
CTDSP1 with Rabeprazole. Previous research suggests the amount of phosphorylated 
DNA-PKcs will increase and the amount of topoI will decrease when CTDSP1 is non 
functional
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SPECIFIC AIMS 
 In order to determine whether downregulation of CTDSP1 contributes to cellular 
resistance to CPT chemotherapy agents, the specific aims of this study were: 
1. To observe the role of CTDSP1 in the topoI degradation pathway after both 
inhibiting CTDSP1with Rabeprazole and then knocking down CTDSP1with siRNA.  
2. To determine the cellular response to CPT after CTDSP1 inhibition. 
3. To determine the change in the rate of CPT induced topoI degradation in CPT 
sensitive cell lines. 
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METHODS 
Developing topoI-pS10 phosphospecific monoclonal antibody: The hybridoma core 
facility of the Dana-Farber Cancer Institute located in Boston provided a mouse 
monoclonal antibody that detected topoI-pS10. The antibody was created using a 
phosphopeptide with the N terminus of topoI with phosphoserine 10. After ELISA assays 
were conducted, 10 clones were selected to use for immunohistochemistry experiments. 
Clone  3573.1C1.H5.H7 was selected for large volume culture and antibody purification 
(Ando et al. 2017).  
Generating the topoI-EGFP HCT15 cell lines: Plasmids were used to create different 
HCT15 cell lines. Single guide-RNA (sgRNA) targeted the topoI stop codon. The goal of 
the sgRNA was to destroy the Streptococcus pyogenes Cas9 (SpCas9)-VQR variant 
binding site after the gene was changed (Kleinstiver 481-5). An EGFP-P2A-Pac fusion 
cassette was used to make the homology regions from HCT15 cells 5’ and 3’ of the topoI 
stop codon. The purpose of using this cassette was to ensure puromycin resistance and to 
create the donor plasmid used in the experiment. Lipofectamine (Lifetechnology) was 
used to transfect the HCT15 cells. PCR amplifying of the genomic locus and sequencing, 
western blot analysis, and immunofluorescence were used to confirm that the genome-
editing cassette was successfully inserted in the single cell cloned HCT15 hTOP1-EGFP 
cells.  Descriptions of other procedures such as DNA-PKcs kinase assays are provided in 
supplementary procedures in the Ando paper (Ando et al. 2017). 
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Editing EGFP in downstream of TopoI: CRISPR/CAS9 genome editing technology 
was used to place the EGFP gene after the hTOP1 gene coding for topoI. The procedure 
is demonstrated in figure 8 below. 
 
 
 
 
 
 
Figure 8: Genomic editing procedure for tagging TopoI to EGFP via insertion into 
mRNA adapted from Nature 2015, Science 2014 
 
CTDSP1 Inhibitor Experiments  
After culturing both resistant cell line HCT15 4E7 and sensitive cell line HCT116 12-
G10 in two different flasks, the cells were first split.  
Cell Splitting: First, the RPMI 1 µg/mL puromycin media and RPMI 2µg/mL puromycin 
media were aspirated from flasks containing HCT116 12-G10 and HCT15 4E7 cells 
respectively. Aspirations were done two times, and then the media was discarded in a 
waste bucket.  
After the addition of 2mL of trypsin, each flask was placed in an incubator for 5 
minutes. Two new tubes were prepared and labeled for each cell line. The trypsin treated 
flasks were removed from the incubator and 6mL of RPMI media was added to each 
flask. The cells were then collected from each flask and put into the new tubes. The new 
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tubes were then centrifuged for 1,500 rpm 5 minutes. Once the tubes were centrifuged, 
cell pellets were visible and the media in each tube was dumped into the waste bucket. 
5mL of fresh RPMI was added into the tubes with cell pellets. The tubes were then 
vortexed.  
Three 6cm dishes with 0µM, 5µM, and 10µM concentrations of Rabeprazole were 
prepared for both cell lines HCT16 4E7 and HCT115 1-2G10. Rabeprazole was ordered 
from Sigma under the catalogue number 1478505. Untreated RPMI media was added to 
the 0µM Rabeprazole plates. To create a 5µM concentration of Rabeprazole in RPMI, 
50µL of 1mM Rabeprazole was added to 10mL of RPMI. To create a 10µM 
concentration of Rabeprazole in RPMI, 100 µL of 1mM Rabeprazole was added to 10mL 
of RPMI.  3mL of each solution were added to their respective 10cm Dishes.  A 1:10 
ratio for cells to mL of RPMI was used to assess how many cells to put into the flask. For 
every 1mL of RPMI, 100µL cells were added. Since 5mL of RPMI solutions were added 
to each tube with the cell pellet, 500µL of cells from the tube with the vortexed cell pellet 
were added to each 6cm dish.  All dishes were placed in the incubator overnight.  
 In addition to the 6cm dishes shown in table 1, two new flasks were prepared for 
each cell line. For cell line HCT15 4E7, 10mL of RPMI with 2µg/mL amount of 
puromycin was added to the flask. For cell line HCT116 12-G10, 10mL of RPMI with 
1µg/mL amount of puromycin was added to the flask. 500µL of cells from the tubes with 
cells vortexed in 5mL of RPMI were added to their respective flasks. Both flasks were 
placed in the incubator for a week to sustain the cell lines before being split again.  
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Treating cells with SN-38: The newly prepared 6cm dishes were removed from the 
incubator after a 72-hour period.  A 2.5µM concentration of SN-38 was added to the 3 
dishes with cell line HCT15 4E7.  To prepare this concentration of SN-38, 25µL SN-38 
was added 10mL of RPMI.  3mL of the SN-38 and RPMI solution were added to each 
HCT115 dish, and the dishes were placed in the incubator for 30 minutes. A 250nM 
concentration of SN-38 was added to the 3 dishes with cell line HCT116 12-G10.  To 
prepare this concentration of SN-38, 2.5µL SN-38 was added 10mL of RPMI.  3mL of 
the SN-38 and RPMI solution were added to each of the HCT116 12-G10 dishes. Dishes 
were placed in the incubator for 60 minutes. 
Cell Lysate Buffer Preparation: The cell lysate buffer used in the experiment 
contained150mM NaCl, 50mM Tris (pH 7.5), 1% NP40, 1mM DTT, 1mM EDTA, 50 µL 
NaF, 50 µL NaV, 50 µL PMSF, 50 µL Pepstatin, and 50 µL Aprotinin as shown in table 2 
of the appendix.. 
The amount of cell lysate buffer was adjusted to achieve the same concentrations listed in 
table 3 of the appendix in a 10mL volume.  
Preparing Cell Lysates: First, all dishes were removed from the incubator and placed on 
ice. The media from each dish was then aspirated and discarded in the waste bucket. 1mL 
of PBS was placed into each dish to wash the cells. The PBS was then aspirated and 
discarded using the 1000µL pipette. 150µL of lysate buffer was added to each dish. After 
adding the lysate buffer, a cell scraper was used to scrape the cells off the plates and 
collect the cells and buffer mixture into 6 newly labeled microtubes using the 1000µL 
pipette. All microtubes were incubated on ice for 30 minutes once filled with the cell 
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lysate mixtures. The 6 microtubes were vortexed and then centrifuged for 15 minutes in 
14,000 RPM, at 4°C. The supernatant was then collected from the microtubes and put 
into newly labeled microtubes using the 200µL pipette in order to avoid collecting the 
pellet. 
Examining the Concentration of the Cells in the Lysate: We prepared the following 
seven microtubes show in table 4 of the appendix. 800µL of water and 200µL Biorad 
Protein assay were added to each tube. 2.5µL of the previously prepared lysis buffer was 
added to the control tube. 2.5µL of each sample was put into their respective microtubes. 
Each tube was then vortexed. A change in color from brown to blue indicates protein 
from the sample is in the microtube.  Contents from the microtube were transferred to 
cuvettes and placed in a spectrophotometer. The spectrophotometer measures the 
absorption of light in the samples compared to the lysate buffer in order to determine the 
concentration of protein in each sample. The absorbance of light of each sample was 
measured at 560nm. The cuvette with lysate buffer was first placed into the 
spectrophotometer to use as a blank. Then the remaining samples were placed into the 
spectrophotometer and the protein concentrations were recorded as OD values.  
Western Blot Analysis: When examining DNA-PKCS, a 5 % gel was prepared. When 
examining topoI, a 7.5% gel was prepared. The Materials used to create a 5% and 7.5% 
gel can be found respectively in table 5 and 6 of the appendix. When examining topoI, a 
7.5% gel was prepared.  
While waiting for 45 minutes for the gel to solidify, 1L of running buffer solution 
was prepared using 100mL of 10X running buffer and 900mL of water. 1L of transfer 
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buffer solution was prepared as well. In a 1000mL-graduated cylinder, we added 100mL 
of 10% methanol, 100mL of 10X transfer buffer, and 800mL of water. After covering the 
graduated cylinder with a parafilm, the solution was put into a cold room at 4° Celcius for 
an hour. After the separating gel hardened, the indicated amount of TEMED was added to 
the stacking gel and the comb inserted into the gel. After 20 minutes, the wells were 
ready to load.  
Preparing the Samples: Lysate samples stored in the -80° freezer were thawed on ice for 
one hour. After thawing was complete, the samples were vortexed. The concentrations of 
each sample were determined using the spectrophotometer, and calculations were done to 
determine the amount of each sample to load into the Western blot.  
Calculations to determine the quantity of each lysate to use in Western Blot: The OD 
values of each sample were compared and the following equation was used to determine 
the µL amount of each sample to add to the western blot. 
Equation 1: [Lowest OD value of all samples/OD value of sample] * 10= (    ) µL  
Making the Western Blot Lysate Buffer: 10% DTT and 90% Lameli sample buffer were 
used to prepare a 100µL solution. 90µL of Lameli sample buffer and 10µL of 1M DTT 
stored in the -20°C freezer were added to a microtube. The newly prepared lysate buffer 
and samples were added to each tube in a 1:1 ratio.  The amount of sample added to each 
microtube was determined by the previous equation using OD values. After adding both 
samples and lysate buffer to microtubes, the microtubes were boiled for 5 minutes and 
then put on ice.  
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Loading the Samples and Electrophoresis: The electrophoresis apparatus was 
assembled, and running buffer was poured in between the two glasses containing the gel. 
5µL of molecular weight marker were added to the first and last wells on the gel. The 
remaining samples mixed with lysate master mix were added to the wells in between. 
Table 7 of the appendix shows the quantity of sample and marker added to each well of 
the western blot gel.  
The remaining running buffer was poured into the apparatus to reach a level that 
completely covered the samples but did not surpass the buffer between the two glass 
plates. The apparatus was plugged into a BioRad 200 power source at 50mV for 
approximately 2 hours. At this point the blue dye had just completed running off the gel 
and was ready to be transferred. The purpose of the electrophoresis was to separate the 
proteins by molecular weight.  
Transferring the Membrane: After completing the protein separation based on size using 
gel electrophoresis, the proteins on the gel were transferred to an Immobilon-P Transfer 
membrane, pore size 0.45µm (Millipore, Billerica, MA) using a wet transfer system 
(BioRad, Hercules. CA). To activate the membrane, the membrane was placed in  
methanol for one minute and then placed in transfer buffer for 5 minutes. Post membrane 
activation, a transferring cassette sandwich was assembled in the following order starting 
on the black side of the cassette: sponge soaked in transfer buffer, 3 pieces of filter paper, 
gel, immunoglobulin membrane, 3 pieces of filter paper, sponge soaked in transfer buffer. 
The cassette was placed in the transfer apparatus and connected to a Biorad Powerpac 
300 apparatus. For a DNA-PKcs western blot, the settings were adjusted to 
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200milliAmps, and the transfer occurred for 2 hours in the 4-degree cold room. For a 
topoI western blot, the settings were adjusted to 10milliAmps, and the transfer occurred 
over night in the 4° cold room.  
Membrane Blocking: To block the DNA-PKcs membrane, the newly transferred 
membrane was soaked in 2% BSA/TBS-T for 1 hour on a rocker. To prepare 2% BSA, 
1g of Albumin Bovine Serum was vortexed with 50mL of 0.05% TBS-T. To block the 
topoI membrane, the newly transferred membrane was soaked in 5% skim Milk and 
0.05% PBS-T solution for 1 hour. To prepare this solution 2.5g of Biorad blotting grade 
buffer was vortexed with 50mL of 0.05% PBS-T. 
Applying the Primary Antibody: 10mL of a primary antibody solution containing anti-
S2056-DNA-PKcs was added to the DNA-PKcs western blot. The membrane covered by 
primary antibody was placed on a rocker in the 4°C cold room overnight. 10mL of 
primary antibody solution containing anti-topoI and anti-βactin was applied to the 
membrane measuring topoI for one hour in a room temperature room on a rocker.  
Washing the Membrane: When using a DNA-PKcs membrane, the membrane was 
soaked 3 times for a period of five minutes in 0.05% TBS-T solution. This buffer is used 
when trying to detect phosphoproteins because we do not want to block phosphate when 
trying to measure DNA-PKcs. To prepare TBS-T, we added 500mL of transfer buffer, 
50mL of 10X TBS, 450mL of distilled water, and 250µL of Tween20. A stirring bar was 
added to the graduated cylinder containing the solution, and the cylinder was covered 
with a parafilm.  When using a topoI membrane, the membrane was soaked for a period 
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of 5 minutes in a 0.05% PBS-T solution. To prepare PBS-T, we added 500mL of transfer 
buffer, 50mL of PBS, 450mL of distilled water, and 250µL Tween. A stirring bar was 
added to the graduated cylinder containing the solution, and the cylinder was covered 
with a parafilm. 
Applying the Secondary Antibody: 3µL of rabbit anti-human IgG secondary antibody 
stored at 4°C was diluted with 9mL 2% BSA/0.05% TBS-T. The dilution was added to 
the DNA-PKcs membrane for one hour. 3µL of mouse anti-human IgG secondary 
antibody stored at 4°C was diluted with 9mL 5% milk/0.05% PBS-T. The dilution was 
added to the topoI membrane for one hour. The same solutions previously discussed were 
used to wash their respective membranes after applying the secondary antibody. For the 
DNA-PKcs western blot, washes were conducted for two 15-minute intervals followed by 
one half hour interval. For the topoI western blot, washes were conducted for three 10-
minute intervals. 
Developing the Membrane: A developing solution was prepared using 800µL of Western 
Lighting Plus ECL oxidizing reagent plus and 800µL of Western Lighting Plus ECL 
enhanced luminol reagent plus. The membrane was sprayed with the developing solution 
and left to sit on a piece of seran wrap for 1 minute. The membrane was then covered 
with a dry piece of seran wrap and then taped inside a Biorad exposure cassette. The 
cassette containing the membrane was taken to a dark room to be developed.  For the 
DNA-PKcs membrane, film was placed into the box for 1 minute 30 seconds. The film 
was then removed from the box, flipped upside down, and placed into the box for 2 
	24 
minutes. The film was then removed again and placed in the film developer.  For the 
topoI membrane, the film was placed into the box for 1 second. The film was then 
removed from the box, flipped upside down, and placed into the box for 2 seconds. The 
film was then removed again and placed in the film developer. After 4 minutes, the 
developer spits out completed films with visible bands. 
Clonogenic Assay:  All materials including plates and pipettes used were sterile. RPMI 
medium and trypsin were warmed at 37 °C for one hour. The media was aspirated from a 
flask of newly grown cells x2 and discarded in the waste bucket. 2mL of Trypsin was 
then put into the flask of HCT116 cells. The flask was then placed into the incubator for 5 
minutes.  6mL of RPMI media was then added to a fresh tube labeled HCT116-1-2G10. 
The tube was then centrifuged at 1,500 RPM for 5 minutes. After centrifuging the tube, 
the media was dumped out into the waste bucket, leaving a cell pellet at the bottom of the 
otherwise empty tube. 5mL RPMI was added into the tube with cell pellet. The tube was 
then vortexed until the cell pellet was completely dissolved in the added media. Table 8 
of the Appendix shows the contents of the 10cm plates of HCT116-1-2G10 cells cultured 
in different Rabeprazole and SN38 conditions. 
 10 mL of RPMI medium was put into plate 1 and 3. These plates contained 0µM 
Rabeprazole. A tube of 20mL RPMI with 200 µL of Rabeprazole was prepared. 10mL of 
this solution was added into Plate 2, and 10 mL of this solution was added into plate 4. 
These dishes contained 10µM Rabeprazole. Put 200 µL of HCT116-1-2G10 cells were 
added into each dish. All dishes were placed into the incubator for 4 days.  After 4 days, 
the 4 plates of cells were divided into two sets of the following 6 well plates and exposed 
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to different concentrations of SN-38 shown in table 9 of the Appendix. 10mM 
concentration SN-38 was used in the following experiment. The contents of the 6-well 
plate with 10µM Rabeprazole treated 12-G10 cells are shown in table 10 of the 
Appendix. 
150µL of 1mM Rabeprazole was put into a tube with 15mL of RPMI to create achieve a 
concentration of 10µM Rabeprazole. SN-38 concentrations were then put into the 
Rabeprazole treated RPMI.  After treatment with SN-38 for 22 hours, the cells were 
counted. 
Counting the cells: After removing the dishes of both treated and non-treated cells from 
the incubator, the media was aspirated and removed from each dish. Cells were then split 
from each of the 6 well plates into 12 cell pellets. After 5 minutes of treatment with 
0.5mL of trypsin, 3mL of RPMI were added to collect and centrifuge the cells. After 
centrifuging the cells, the media was dumped out and 1mL of fresh RPMI was added to 
12 microtubes. 800µL PBS, 100µL trypsin, and 100µL of cells were added to 12 new 
microtubes. Cells were then counted under the microscope. Before examining cells under 
the microscope on the slides, the medium with cells was pipetted up and down in order to 
further detach the cells. Cell counting data is shown in table 11-14 of the Appendix.  
After counting the cells, six 6-well dishes were created: 3 for control 0µM Rabeprazole 
and 3 for 10µM Rabeprazole. The goal was to add 10 cells/1µL to the assigned dish, and 
in each well there was a total of 5µl of media.  
The dishes were then placed in the incubator for 50 hours and then the formation of 
clones was assessed.  
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Immunofluorescent Staining of pDNA-PKcs: A 6-well dish was created using the 
HCT116 cell line exposed to different concentrations of Rabeprazole. The contents of the 
6 well-dish are shown in table 15 of the Appendix. 50µL Rabeprazole were put into in 
5mL RPMI media to achieve a 10µM concentration of Rabeprazole. After filling the 
wells with media, a slide was placed at the bottom of each dish. After four days of 
treatment, the cells were prepared for immunofluorescent staining. 
Fixing the Cells 
After aspirating and discarding the media, the dishes were washed twice with 1mL of 
PBS. 1mL of 3.7% Formaldehyde was then added to each dish for a 15-minute period.  
Permeabilizing the cells 
The Formaldehyde solution was then aspirated and washed twice with 1mL of PBS. 1mL 
of 0.2% PBS-T was then added to each well for a 10-minute period. The 0.2% PBS-T 
was then aspirated and washed twice with 1mL of 0.01% PBS-T.  
Blocking the cells  
1 mL of 3%BSA/0.01% PBS-T was added to each well for one hour.  
Adding the primary antibody: anti pDNA-PKcs and  p-TopoI 
200µL 3% BSA/0.01% PBS-T and 400µL 0.01%PBST were added to a microtube to 
make a 600µL 1% BSA/0.01% PBS-T solution. A western blot gel square was placed on 
top of the western blot wash square. Both squares combined were placed in a larger wash 
box and a parafilm was placed on top of the western blot wash square. 6 µL of primary 
antibody were placed into the 600µL microtube solution to achieve a 1:100 concentration. 
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Four 100µL dots of the solution were pipetted on to a parafilm. The 4 slides from the 6-
well plate were placed on a 100µL dot for 1 hour.  
Adding the secondary antibodies: α-Rb-Green, α-MS-Red 
The slides were removed from the parafilm and placed back in their respective wells of 
the 6-well plate. All slides were washed twice with 0.01%PBST for 5 minutes. 200µL 3% 
BSA/0.01% PBS-T and 400µL 0.01%PBST were added to a microtube to make a 600µL 
1%BSA/0.01% PBS-T solution. 1.2µL secondary antibody was added to the 600µL 
solution to achieve a 1:500 concentration. Four 100µL dots of the solution were pipetted 
on to a parafilm. The 4 slides from the 6-well plate were placed on a 100µL dot for 45 
minutes. 
Adding DAPI 
The slides were placed back into the wells. 0.1% concentration of DAPI, 4',6-diamidino-
2-phenylindole, was added to each well.  
Mounting the cells 
4 drops of Prolong Diamond Antifade mounting medium were added to a parafilm. The 
slides were placed on the parafilm with the cells facing the drop. After 24 hours the cells 
were ready to be viewed under the microscope.  
Image of topoI-EGFP:  HCT116 cell lines with topoI-EGFP fusion proteins were 
incubated with 0,5, and 10µM Rabeprazole concentrations. Generation of topoI-EGFP 
fusion proteins was discussed earlier in the methods section. After 4 days, cells were 
visualized under the Leica S5 confocal microscope to examine the effects of Rabeprazole 
on topoI levels. Cells containing topoI tagged to EGFP revealed a bright green color. 
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CTDSP1 Knock Down Experiments  
Dharmacon siRNA Resuspension: First, we acquired 5nmol CTDSP1(58190) siRNA 
capable of knocking out CTDSP1 from Dharmacon Pharmaceuticals. We then 
centrifuged the tube of siRNA powder. In order to prepare a 20µM stock of the siRNA 
suspension, we added 50µL of 5x siRNA buffer and 200µL of Nuclease free water to the 
tube.  siRNA Resuspension volumes and concentrations are shown in table 16 of the 
appendix.  
 We pipetted the solution up and down four times and let the solution mix in the 
Eppendorf Mixer 5432 for 30 minutes. After centrifuging, we added 25µL of the siRNA 
suspension into ten individual microtubes to attain a 250nM concentration. The 
microtubes were then centrifuged and the siRNA concentration was confirmed using UV 
spectrophotometry at 260nm. 1µM of siRNA is equal to 13.3ng/µL.  We achieved a 
reading of 249.5ng/µL for a 5nmol amount of siRNA. We then placed the CTDSP1 
siRNA in the -20°C freezer overnight.  
Transfecting the Cells: We plated cell lines HCT116 and 12-G10 and waited until cell 
growth was 70-90% confluent. Two 6-well dishes shown in table were prepared for each 
cell line. The contents of each dish are shown in Table 17 and Table 18 of the Appendix. 
500µL of RPMI and 4µL of Lipofectamine 3000 Reagent were added to each of the four 
wells. 1.5µL of 20µM CTDSP1 siRNA was added to two wells of the 6-well dish for 
each cell line. After waiting 20 minutes, we then added 50µM cells to their respective 6-
well dishes. Once the cells were added, we waited 48 hours for the cells to incubate in the 
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transfection materials. Once the cells were added, we waited 48 hours for the cells to 
incubate in the transfection materials.  
Lysate Preparation:  We then treated two wells from each 6-well plate with SN-38. One 
well treated contained siRNA, and one well treated contained no siRNA to act as a 
control. We prepared the following lysates for the CTDSP1 knock down experiments 
using the same methodology as the CTDSP1 inhibitor experiments discussed previously.  
Cell lines with and without functional CTDSP1 were evaluated in both control conditions 
and after exposure to SN-38. The lysates prepared are shown in table 19 of the Appendix. 
After preparing the lysates, we measured concentration of protein in the lysates using the 
same methods discussed previously.  
Western Blot Analysis: We conducted three types of western blots for CTDSP1 knock 
down experiments. Like the CTDSP1 inhibitor experiments, we looked at the amount of 
DNA-PKcs phosphorylation and topoI. We also conducted the additional western blot to 
confirm the knockdown of CTDSP1 in both HCT116 and 12-G10 cell lines.  When 
examining DNA-PKcs, a 5 % gel was prepared. When examining topoI, a 7.5% gel was 
prepared. Lastly, when checking for the presence of CTDSP1, a 10% gel was prepared. 
Materials used to create the 10% gel are shown in table 20 of the Appendix. The same 
methods used for the inhibitor experiments were used to produce the CTDSP1 
knockdown western blots. For the western blot determining whether or not CTDSP1 was 
successfully knocked down in each cell line, we used the primary antibody anti-CTDSP1. 
All other conditions for this western blot were identical to those used for topoI western 
blots.  
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Immunofluorescent Staining of pDNA-PKcs:  The same methods used in the inhibitor 
experiments were used to evaluate the immunofluorescence of pDNA-PKcs after 
CTDSP1 knockdown with and without SN-38 exposure in cell lines HCT116 and 12-
G10. 
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RESULTS 
 
Inhibitor Experiment: 
Western Blot Data 
 CPT resistant HCT-15-4E7 and sensitive HCT116 12-G10 cell lines were treated with 
Rabeprazole, an inhibitor of CTDSP1. We hypothesized when both SN-38 incubated cell 
lines were treated with Rabeprazole, CTDSP1 would be inhibited and unable to remove 
the phosphate from DNA-PKcs. This would result in greater phosphorylation of DNA-
PKcs post Rabeprazole treatment. We also hypothesized greater phosphorylation of 
DNA-PKcs would be observed in HCT-15 resistant cell lines. Figure 9 shows when 
concentrations of Rabeprazole are increased, phosphorylation of DNA-PKcs is increased 
in both resistant and sensitive cell lines. The greatest amount of phosphorylated DNA-
PKcs is observed in Lane 3, which represents resistant cell line HCT-15 with exposure to 
10µM Rabeprazole. Figure 9 shows cells treated with greater concentrations of 
Rabeprazole produced darker, more prominent bands at the molecular mark 
phosphorylated DNA-PKCS is expected to be. 
Figure 9:  
Phosphorylation of DNA-PKCS in 
cells is enhanced after CTDSP1 
inhibition with Rabeprazole: CPT-
treated 4E7-HCT15 (lanes 1-3) and 
HCT116-12-G10 cell lysates (lanes 4-6) 
were analyzed by immunoblot analysis 
with anti-DNA-PKcs. Both lanes 1-3 and 
lanes 4-6 of represent cells exposed to 
0µM, 5µM, and 10µM concentrations of 
Rabeprazole respectively. The band 
generated by phosphorylated DNA-PKcs 
appears around 460 Kda 
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To further explore the relationship between CTDSP1 inhibition and DNA-PKcs 
phosphorylation in sensitive cell lines, a western blot was conducted using cells from line 
HCT116-1-2G10 exposed with 0µM, 5µM, or 10µM concentrations of Rabeprazole. 
Additionally, only half of the cell lines were treated with SN-38 to determine whether 
Rabeprazole induced changes were only observable in cells incubated with SN-38 
Figure 10 shows greater phosphorylation of DNA-PKcs in lanes 2 and 3 
compared to lane 1, suggesting that exposure to increased amounts of Rabeprazole results 
in greater phosphorylation of DNA-PKcs in cell line HCT116 without SN38 treatment. In 
cell line HCT116-12-G10, the greatest amount of DNA-PKcs phosphorylation is 
observed in Lane 5, representing incubation with 5µM concentration of Rabeprazole. The 
greater phosphorylation of DNA-PKcs in cells observed in Lane 5, treated with 5µM 
Rabeprazole, in comparison to Lane 4, treated with 0µM Rabeprazole supports the role of 
CTDSP1 as a regulator of DNA-PKcs. 
Figure 10: Phosphorylation of DNA-
PKCS in CPT treated cells is 
enhanced after CTDSP1 inhibition 
with Rabeprazole: Control HCT116-
12-G10 (lanes 1-3) and CPT treated 
HCT116-12-G10 cell lysates (lanes 4-6) 
were analyzed by immunoblot analysis 
with anti-pDNA-PKcs. Both lanes 1-3 
and lanes 4-6 of represent cells exposed 
to 0µM, 5µM, and 10µM concentrations 
of Rabeprazole respectively. The band 
generated by phosphorylated DNA-PKcs 
appears around 460 Kda.  
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Greater phosphorylation of DNA-PKcs observed when HCT116 cell line was 
exposed to 5µM Rabeprazole compared to 10µM Rabeprazole observed in lane 5 and 6 of 
Figure 10 led to continued investigation of the effects of CTDSP1 inhibition on sensitive 
cell line HCT116-1-2G10 exposed to 0µM and 5µM Rabeprazole concentrations. 
Both lanes 1 and 3 in Figure 11, exposed to 5µM Rabeprazole, reveal 
significantly greater amounts of DNA-PKcs phosphorylation in comparison to lanes 2 
and 4 in Figure 11, exposed to 0µM Rabeprazole. HCT116 treated with both SN-38 and 
5µM Rabeprazole in lane 3 shows the greatest amount of DNA-PKcs phosphorylation 
and the darkest band.    
 
Figure 11: Phosphorylation of 
DNA-PKCS in CPT treated 
cells is enhanced after CTDSP1 
inhibition with Rabeprazole: 
CPT treated HCT116-12-G10 
(lanes 1-2) and control HCT116-
12-G10 cell lysates (lanes 3-4) 
were analyzed by immunoblot 
analysis with anti-pDNA-PKcs. 
Both lanes 1-2 and lanes 3-4 of 
represent cells exposed to 5µM 
and 0µM of Rabeprazole 
respectively. The band generated 
by phosphorylated DNA-PKcs 
appears around 460 Kda. 
 
 
After producing the results shown in figure 11, an experiment using the same 
conditions was conducted to determine whether the results were reproducible. Similar to 
the last experiment, the darkest band and greatest amount of DNA-PKcs phosphorylation 
occurred in HCT116 cells treated with both SN-38 and 5µM Rabeprazole. 
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Figure 12: Phosphorylation of DNA-PKCS in 
CPT treated cells is enhanced after CTDSP1 
inhibition with Rabeprazole: CPT treated 
HCT116-12-G10 (lanes 1-2) and control HCT116-
1-2G10 cell lysates (lanes 3-4) were analyzed by 
immunoblot analysis with anti-DNA-PKcs. Both 
lanes 1-2 and lanes 3-4 of represent cells exposed 
to 5µM and 0µM of Rabeprazole respectively.  
 
 
 
 
 
Cellular levels of topoI were also evaluated in both HCT-15-4E7 and HCT116-
12-G10 cell lines after exposure to 0,5, and 10µM concentrations of Rabeprazole. In 
order to observe the effects of CPT on the degradation of topoisomerase, some cells from 
each Rabeprazole condition were exposed to SN-38. When phosphorylated, DNA-PKcs 
carries out a kinase function and phosphorylates topoisomerase. The phosphorylation of 
topoI proteins leads to ubiquitination followed by degradation of topoisomerase. Without 
topoisomerase, the substrate for CPT to react with is gone, and cells are more resistant to 
the chemotherapy treatment. CTDSP1 is a phosphatase negatively regulates DNA-PKcs 
by dephosphorylating and inactivating the kinase. Inactivation of DNA-PKcs prevents the 
phosphorylation and degradation of topoI that causes resistance.  
We hypothesized that by inhibiting CTDSP1 using Rabeprazole, less topoI would 
be present in the cell due to greater degradation caused by constitutively active DNA-
PKcs. We also hypothesized that treatment with SN-38 initiated the degradation pathway, 
leading to even less topoI in cells treated with both Rabeprazole and SN-38.  Both 
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resistant cell line HCT-15-4E7 and sensitive cell line HCT116-1-2G10 were evaluated in 
Figure 13.  
We expected to see the greatest amount of topoI degradation in the HCT15 cell 
line, since this cell line is resistant to CPT. Figure 13 reveals complete degradation of 
topoI in lanes 1 through 3 representing HCT15 cells, regardless of Rabeprazole 
concentration.   However, sensitive HCT116 cells demonstrate greater degradation of 
topoI with higher concentrations of Rabeprazole. Lane 6 shows the greatest amount of 
degradation. This data suggests that inhibiting CTDSP1 to a greater degree enhances the 
degradation of topoI in sensitive cell lines. 
 
Figure 13: Greater degradation 
of TopoI occurs in cells after 
CTDSP1 inhibition with 
Rabeprazole: CPT-treated 4E7-
HCT15 (lanes 1-3) and HCT116-
12-G10 cell lysates (lanes 4-6) 
were analyzed by immunoblot 
analysis with anti-topoI and anti-
β-Actin. Both lanes 1-3 and lanes 
4-6 of represent cells exposed to 
0µM, 5µM, and 10µM 
concentrations of Rabeprazole 
respectively.  
 
 The effects of SN-38 and Rabeprazole on the sensitive HCT116 cell line were 
further explored in a follow up western blot shown in Figure 14. Lane 1 produced the 
darkest topoI band and contained cells treated without Rabeprazole and SN-38. Fainter 
topoI bands were observed in the latter 2 lanes exposed to SN-38. Lane 2, treated with 
5µM Rabeprazole, revealed a somewhat fainter topoI band than the band in Lane 1.  
	36 
Figure 14 reveals similar results to figure 5, suggesting that treatment with SN-38 and 
Rabeprazole lead to lower levels of topoI.  
 
Figure 14:  
Greater degradation of TopoI occurs in 
cells after CTDSP1 inhibition with 
Rabeprazole: HCT116-12-G10 (lanes 1-
2) and control HCT116-12-G10 cell 
lysates (lanes 3-4) were analyzed by 
immunoblot analysis with anti-topoI and 
anti-β-Actin. Both lanes 1-2 and lanes 3-4 
represent cells exposed to 0µM and 5µM 
concentrations of Rabeprazole. 
 
 
 
Clonogenic Assay Data: A clonogenic assay was conducted in order to compare the 
survival of HCT116 cells exposed to 10µM Rabeprazole and 0µM Rabeprazole after 
incubation with varying concentrations of SN-38. 
Cell Counting Data: The HCT116 cells from the 0µM Rabeprazole control condition 
were first counted. 
Table 21: Amount of Control HCT116 cells exposed to varying concentrations of 
SN-38 
SN38 concentration Cells # Well 1 Cell # Well 2 Cell # Well 3 
0nM 45 41 43 
0.5nM 27 24 34 
1.0nM 18 0 15 
2.5nM 10 8 11 
5.0nM 1 1 0 
7.5nM 0 1 0 
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The amount of HCT116 cells exposed to 0nM SN-38 in each well were then converted to 
a percentage shown in the table below.  
Table 22: Percentage of control HCT116 cells remaining after exposure to varying 
concentrations of SN-38 
0nM SN-38 Concentration Percentage of Cells (PE) (cell colony 
#/50*100) 
Well 1 
45/(50*100) 
90 
Well 2 
41/(50*100) 
82 
Well 3  
43/ (50*100) 
86 
PE Average  86 
50*PE Average 4300 
 
The surviving fraction for HCT116 cells exposed to 0µM Rabeprazole was calculated for 
each SN-38 condition. 
Surviving Fraction Calculation: Cell colony number in well/50*PE Average 
The PE Average=86 
86*50=4300 
 
Example: Well 1 Surviving fraction 
45/ 4300 = 0.010465116 
 
Table 23: Surviving Fraction of control HCT116 cells after exposure to varying 
concentrations of SN-38 
 
 Well 1 Well 2 Well 3 SF Average 
Surviving 
Fraction 0nM 
wells 
0.010465116 
 
0.009534884 
 
0.01 
 
0.01 
 
Surviving 
Fraction 0.5 
nM wells 
0.00627907 
 
0.005581395 
 
0.007906977 
 
0.006589147 
 
Surviving 
Fraction 1.0 
nM wells 
0.004186047 
 
0 
 
0.003488372 
 
0.003837209 
 
Surviving 
Fraction 2.5 
0.002325581 
 
0.001860465 
 
0.00255814 
 
0.002248062 
 
	38 
nM wells 
Surviving 
Fraction 5.0 
nM wells 
0.000232558 
 
0.000232558 
 
0 0.000155039 
 
Surviving 
Fraction 7.5 
nM wells 
0 
 
0.000232558 
 
0 
 
7.75194E-05 
 
 
The HCT116-1-2G10 cells from the 10µM Rabeprazole control condition were then 
counted. 
 
Table 24:  Amount of 10µM Rabeprazole incubated HCT116-1-2G10 cells exposed 
to varying concentrations of SN-38 
SN38 concentration Cell # Well 1 Cell # Well 2 Cell #Well 3 
0nM 39 46 0 
0.5nM 45 0 48 
1.0nM 41 33 41 
2.5nM 0 16 28 
5.0nM 5 7 3 
7.5nM 4 3 3 
 
 
The amount of HCT116 cells exposed to 0nM SN-38 in each well were then converted to 
a percentage shown in the table below.  
Table 25: Percentage of 10µM Rabeprazole incubated HCT116-1-2G10 cells 
exposed to varying concentrations of SN38 
0nM SN-38 Concentration Percentage of Cells (PE) (cell colony 
#/50*100) 
Well 1 
39/(50*100) 
78 
Well 2 
46/(50*100) 
92 
Well 3  0 
	39 
0/ (50*100) 
PE Average  85 
50*PE Average 4250 
 
The surviving fraction for HCT116 cells exposed to 0µM Rabeprazole was calculated for 
each SN-38 condition. 
Table 26: Surviving Fraction of 10µM Rabeprazole incubated HCT116-1-2G10 cells 
exposed to varying concentrations of SN-38 
 
 Well 1 Well 2 Well 3 SF Average 
Surviving 
Fraction 0nM 
wells 
0.009176471 
 
0.010823529 
 
 
0 
 
0.01 
 
 
Surviving 
Fraction 0.5 
nM wells 
0.010588235 
 
0 0.011294118 
 
0.010941176 
 
Surviving 
Fraction 1.0 
nM wells 
0.009647059 
 
0.007764706 
 
 
0.009647059 
 
0.009019608 
 
Surviving 
Fraction 2.5 
nM wells 
0 0.003764706 
 
0.006588235 
 
0.005176471 
 
Surviving 
Fraction 5.0 
nM wells 
0.001176471 
 
0.001647059 
 
0.000705882 
 
0.001176471 
 
Surviving 
Fraction 7.5 
nM wells 
0.000941176 
 
 
0.000705882 
 
 
0.000705882 
 
 
0.000784314 
 
 
 
We compared the average survival fraction of HCT116 cells exposed to 0µM and 
10µM concentrations of Rabeprazole after SN-38 treatment in order to determine the 
influence of Rabeprazole on HCT116 cell survival after exposure to SN-38. Table 27 
shows the survival rate of HCT116 cells treated with 10µM Rabeprazole increases in 
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comparison to HCT116 cells treated with 0µM Rabeprazole with increasing 
concentrations of SN-38.  
Table 27: Average Survival Fraction Comparison between 0µM Rabeprazole 
incubated HCT116-1-2G10 cells and 10µM Rabeprazole incubated HCT116 cells 
exposed to SN-38 
 
SN-38 exposure 
concentrations 
Control HCT116 10µM Rabeprazole 
treated HCT116 
0nM 0.01 
 
0.019019608 
 
0.5nM 0.006589147 
 
0.010941176 
 
1.0nM 0.003837209 
 
0.009019608 
 
2.5nM 0.002248062 
 
0.005176471 
 
5.0nM 0.000155039 
 
0.001176471 
 
7.5nM 7.75194E-05 
 
0.000784314 
 
 
Table 28 reveals the standard deviations between wells evaluating similar 
conditions. A large standard deviation margin is notable at the 2.5nM SN-38 
concentration, suggesting this data may be less reliable than the other values. The 
remaining values have smaller error margins.  
Table 28: Standard Deviation Survival Fraction Comparison between control 
HCT116 cells and 10µM Rabeprazole incubated HCT116-1-2G10 cells exposed to 
SN-38 
 
SN-38 exposure 
concentrations 
Control HCT116 10µM Rabeprazole 
treated HCT116 
0nM 0.000465116 0.001164646 
 
0.5nM 
 0.001193396 0.000499134 
1.0nM 
 0.00049333 0.001086777 
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2.5nM 
 0.000355238 0.001996537 
5.0nM 
 0.000134268 0.000470588 
7.5nM 
 0.000134268 0.000135847 
 
Below, Figure 15 graphically visualizes the data presented in Tables 27 and 28. 
The blue line represents the control condition of HCT116 cells exposed to 0µM 
Rabeprazole. The red line signifies the HCT116 cells exposed to 10µM Rabeprazole. The 
graph demonstrates no observable difference between the control and Rabeprazole 
treatment conditions when exposed to 0nM SN-38. Additionally, the graph suggests that 
Rabeprazole treated HCT116 cells have a greater survival fraction when exposed to SN38 
compared to control HCT116 cells. The survival fraction of both treated and untreated 
HCT116 cells is lowest at 5.0 and 7.5 nM concentrations of SN-38. Although the survival 
fraction of Rabeprazole treated HCT116 cells is greater than the controls after SN-38 
treatment, the survival of treated HCT116 cells is greatest at the lowest 0 and 0.5 nM 
concentrations of SN-38. 
 
Figure 15: Survival 
Fraction of HCT116 cells 
treated with 0µM and 
10µM concentrations of 
Rabeprazole at different 
SN-38 concentrations 
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Immunofluorescent Staining of pDNA-PKcs Results: 
 
The effects of Rabeprazole on the amount of phosphorylated DNA-PKcs present 
in cell line HCT116-1-2G10 was investigated using immunofluorescent staining. 
HCT116 cells exposed to both 0µM and 10µM concentrations of Rabeprazole were 
treated with anti pDNA-PKcs primary antibody and α-Rb-Green secondary antibody. If 
there were greater levels of pDNA-PKcs in the cells, then the cells would stain a 
fluorescent green.  As a control, all HCT116 cells were also stained with DAPI (4',6-
diamidino-2-phenylindole), a fluorescent blue stain that binds strongly to A-T rich 
regions in DNA.  Therefore, the DAPI stain shows up in the nuclear region of HCT116 
cells treated both 0µM and 10µM concentrations of Rabeprazole. All microscope 
photograph comparisons were taken at the same location on the slide. We hypothesized 
greater levels of pDNA-PKcs would be present in the HCT116 cells treated with 10µM 
Rabeprazole in comparison to cells exposed to 0µM Rabeprazole. Rabeprazole inhibits 
CTDSP1, which prevents the dephosphorylation of DNA-PKcs. Phosphorylated DNA-
PK is the active form of the kinase responsible for phosphorylating and initiating the 
degradation pathway of topoI. We expected to see a greater amount of green fluorescence 
in the HCT116 cell line treated with 10µM Rabeprazole compared to the 0µM 
Rabeprazole HCT116 cells. Additionally, we expected to see no difference in the DAPI 
stain, blue immunofluorescence, between the HCT116 cell groups.   Figure 16A shows 
the pDNA-PKcs green staining of HCT116 cells exposed to 0µM Rabeprazole. Figure 
16B shows the DAPI staining of HCT116 cells exposed to 0µM Rabeprazole. The 
photographs below exhibit the exact same region of the microscope set to different stain 
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settings.  These results suggest that under the control Rabeprazole condition, almost no 
DNA-PKcs is phosphorylated in any HCT116 cells.  
 
 
 
 
 
 
 
Figure 16A: α-Rb-Green Immunofluorescent stain detecting phosphorylated DNA-
PKCS in HCT116 cells treated with 0µM Rabeprazole: HCT116 cells were treated 
with the primary antibody anti pDNA-PKCS and secondary antibody α-Rb-Green. A 
small green fluorescent speck of pDNA-PKCS was revealed under the microscope. 16B: 
DAPI blue Immunofluorescent stain detecting A-T rich regions in DNA in HCT116 
cells treated with 0µM Rabeprazole 
 
The photographs below exhibit the exact same region of the microscope set to 
different stain settings.  These microscope photographs further suggest that under the 
control Rabeprazole condition, there is little DNA-PKcs phosphorylation in HCT116 
cells.  
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Figure 17A: α-Rb-Green Immunofluorescent stain detecting phosphorylated DNA-
PKCS in HCT116 cells treated with 0µM Rabeprazole. HCT116 cells were treated 
with the primary antibody anti pDNA-PKCS and secondary antibody α-Rb-Green. A 
small green fluorescent speck of pDNA-PKCS was revealed under the microscope. 17B: 
DAPI blue Immunofluorescent stain detecting A-T rich regions in DNA in HCT116 
cells treated with 0µM Rabeprazole 
17C: α-Rb-Green and DAPI blue Immunofluorescent stain superimposed on one 
another in HCT116 cells treated with 0µM Rabeprazole. This figure demonstrates the 
images in 8A and 8B are taken from the same frame. 
 
Figure 18A shows the pDNA-PKcs green staining of HCT116 cells exposed to 
10µM Rabeprazole. Figure 18B shows the DAPI staining of HCT116 cells exposed to 
10µM Rabeprazole.  Figure 18C reveals the pDNA-PKcs green stain superimposed upon 
the DAPI stain of HCT116 cells. The photographs below exhibit the exact same region of 
the microscope set to different stain settings.  These results suggest that under the 10µM 
Rabeprazole condition, a greater amount of DNA-PKcs is phosphorylated in comparison 
to the control condition.  
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Figure 18A: α-Rb-Green Immunofluorescent stain detecting phosphorylated DNA-
PKcs in HCT116 cells treated with 10µM Rabeprazole 
18B: DAPI blue Immunofluorescent stain detecting A-T rich regions in DNA in 
HCT116 cells treated with 10µM Rabeprazole 
18C: α-Rb-Green and DAPI blue Immunofluorescent stain superimposed on one 
another in HCT116 cells treated with 10µM Rabeprazole  
 
Figure 19 shows a zoomed in version of the images displayed in Figure 10.  
 
Figure 19A: α-Rb-Green Immunofluorescent stain detecting phosphorylated DNA-
PKcs in HCT116 cells treated with 10µM Rabeprazole 
19B: DAPI blue immunofluorescent stain  
19C: α-Rb-Green and DAPI blue Immunofluorescent stain superimposed on one 
another in HCT116 cells treated with 10µM Rabeprazole 
 
 
Image of topoI-EGFP Results: 
 
The effects of Rabeprazole on the amount of topoI present in cell line HCT116 
was investigated by tagging EGFP to topoI.  Figure 20 shows the EGFP fluorescence of 
HCT116 cells were incubated with 0, 5, and 10µM concentrations of Rabeprazole. 
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Inhibition of CTDSP1 results in greater DNA-PKcs phosphorylation and topoI 
degradation. We hypothesized that HCT116 cells exposed to greater concentrations of 
Rabeprazole, a CTDSP1 inhibitor, would have lower levels of topoI and present a 
decreased amount of EGFP fluorescence. Figure 20 reveals the greatest amount of topoI-
EGFP fluorescence in cells incubated with 0µM Rabeprazole and the least amount of 
topoI-EGFP fluorescence in cells incubated with 10µM Rabeprazole. Less topoI-EGFP 
fluorescence with increasing amounts of Rabeprazole suggests that inhibition of CTDSP1 
enhances topoI degradation in HCT116 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Visualization of TopoI EGFP in HCT116-1-2G10 cells treated with 0µM, 
5µM and10µM concentrations of Rabeprazole  
 
CTDSP1 Knockdown Experiments 
Western Blot Data: 
The results of the inhibitor experiments suggest an influence of CTDSP1 on the 
topoI degradation pathway in sensitive cell lines. We decided to see if similar findings 
could be produced in sensitive cell lines HCT116 and 12-G10 after knocking down 
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CTDSP1 completely using siRNA. We expected to observe greater DNA-PKcs 
phosphorylation in cell lines in the CTDSP1 knock down condition, for CTDSP1 is the 
phosphatase that removes the phosphate from DNA-PKcs. We also hypothesized that the 
magnitude of DNA-PKcs phosphorylation would be enhanced in cell lines exposed to 
SN-38, which in previous experiments appeared to jumpstart the degradation pathway.  
Lane 1 revealed no band for DNA-PKcs phosphorylation and contained cell line HCT116 
with functional CTDSP1 and without exposure to SN-38. In contrast, lane 2, also 
containing functional CTDSP1 did produce a pDNA-PKcs band. The only difference 
between lanes 1 and 2 was incubation of HCT116 cells with SN-38 in lane 2. This 
suggests that SN-38 treatment contributes to greater phosphorylation of DNA-PKcs even 
when CTDSP1 is functional. Lanes 5 and 6 demonstrate the pDNA-PKcs band produced 
by cell line 12-G10 with functional CTDSP1. Lane 6, the condition with SN-38 
treatment, shows a darker band than lane 5. This evidence further supports the role of 
SN-38 as a contributing factor to greater DNA-PKcs phosphorylation. The light band 
produced in Lane 8, demonstrating the CTDSP1 knockdown after incubation with SN-38 
deviates from our expectations. In this situation, we would expect a darker band since 
there is no phosphatase present to dephosphorylate DNA-PK.  
Figure 21:  
Phosphorylation of DNA-PKCS in cells is 
enhanced both after incubation with CPT: 
HCT116 (lanes 1-4) and HCT116-12-G10 (lanes 
5-8) cell lysates were analyzed by immunoblot 
analysis with anti-pDNA-PKcs. The band 
generated by phosphorylated DNA-PKcs appears 
around 460 Kda. Lysates in lanes 2,4,6, and 8 
were treated with CPT. Lanes 3,4,7,and 8 
demonstrate CTDSP1 knock down conditions.  
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Because of the discrepancy seen in results from the previous pDNA-PKCS 
experiment, we decided to conduct an additional western blot shown in Figure 22 to 
examine pDNA-PKCS levels after CTDSP1 knockdown and SN-38 treatment. While the 
control conditions shown in lanes 1 and 2 looked relatively similar, there were 
differences observed between the CTDSP1 knock down conditions observed in lanes 3 
and 4. A fainter band is observed in lane 3, which represents the CTDSP1 knockdown 
without SN-38 treatment. The darkest band is shown in lane 4, which represents the 
CTDSP1 knockdown and SN-38 incubation. These results further suggest the enhanced 
effect on DNA-PKcs phosphorylation produced when both CTDSP1 is knocked down 
and cells are treated with SN-38.  Lanes 5 and 6, containing cell line 12-G10 in the 
control condition, produced bands that demonstrate differences in DNA-PKcs 
phosphorylation after exposure to SN-38. The pDNA-PKcs band in Lane 6 is darker than 
the one produced in lane 5. These results also support the idea that greater 
phosphorylation of DNA-PKcs occurs in cells after exposure to SN-38. Lanes 7 and 8 
showed bands produced by cell line 12-G10 after CTDSP1 knockdown. The contrast 
between these bands is greater than the contrast between lanes 5 and 6, suggesting 
treatment with SN-38 has more pronounced effects on cells lacking functional CTDSP1 
relative to controls. Lane 8 produced the darkest band for the 12-G10 cell line, meaning 
the greatest phosphorylation of DNA-PKcs occurred in cells lacking CTDSP1 and 
incubated with SN-38. Unlike the previous blot, the protein concentrations in Figure 22 
appear more consistent between lanes.  
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Figure 22: Phosphorylation of DNA-PKCS in 
cells is enhanced both after CTDSP1 knock 
down and incubation with CPT:	 
HCT116 (lanes 1-4) and HCT116-12-G10 
(lanes 5-8) cell lysates were analyzed by 
immunoblot analysis with anti-DNA-PKcs. The 
band generated by phosphorylated DNA-PKcs 
appears around 460 Kda. Lysates in lanes 2,4,6, 
and 8 were treated with CPT. Lanes 3,4,7,and 8 
demonstrate CTDSP1 knock down conditions. 
  
After knocking down CTDSP1 in cell lines HCT116 and 12-G10, we also 
demonstrated the amount of topoI present in the cells after treating with and without SN-
38 in Figure 23. We expected CTDSP1 knockdown cells to lead to greater DNA-PKcs 
phosphorylation and subsequent topoI degradation. Additionally, we suspected treatment 
with SN-38 would accelerate the topoI degradation process. No notable significant 
differences were noticed in bands produced by the HCT116 cell line. The faintest band 
was produced in Lane 8, which represents cell line 12-G10 with both CTDSP1 knock 
down and SN-38 exposure. Lane 8 produced a significantly darker actin band than the 
other lanes, suggesting that a greater concentration of protein was present in this 
condition compared to the other bands. However, even with extra protein, lane 8 still 
produced a lighter band.  
 
Figure 23:  
Greater degradation of TopoI occurs in cells 
after CTDSP1 knockdown and CPT exposure: 
HCT116 (lanes 1-4) and HCT116-12-G10 (lanes 5-
8) cell lysates were analyzed by immunoblot 
analysis with anti-topoI and anti-β-Actin. Lysates 
in lanes 2,4,6, and 8 were treated with CPT. Lanes 
3,4,7,and 8 demonstrate CTDSP1 knock down 
conditions. The top and bottom bands show levels 
of topoI and actin respectively. 
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 For the previous results to be valid, we needed to confirm the knockdown of 
CTDSP1 was successful. We conducted the western blot shown in Figure 24 to test for 
the presence of CTDSP1. The dark bands produced in lanes 1,2, 5, and 6 show the 
presence of CTDSP1 protein. The fainter bands are produced in lanes representing the 
CTDSP1 knockdown condition for both cell lines demonstrate that the knockdown of 
CTDSP1 was successful. These results also indicate that the experiments examining 
pDNA-PKcs and topoI shown above are portraying the contrast between CTDSP1 
knockdown and normal control cells.   
Figure 24 Confirmation of CTDSP1 
knockdown: HCT116 (lanes 1-4) and 
HCT116-12-G10 (lanes 5-8) cell 
lysates were analyzed by immunoblot 
analysis with anti-CTDSP1. Lanes 
3,4,7,and 8 demonstrate CTDSP1 
knock down conditions. CTDSP1 is an 
approximately 31.2 Kda protein 
 
 
 
 
 After examining the effects of knocking down CTDSP1 on both cell lines 
HCT116 and 12-G10, the results for cell line HCT116 were not conclusive. In order to 
provide further evidence for the role of CTDSP1 in the topoI degradation pathway in cell 
line HCT116, we conducted an additional Western Blot. Both lanes 1 and 2 in Figure 25 
produced lighter topoI bands in comparison to lanes 3 and 4. Similar to previous blots, 
these results suggest knocking down CTDSP1 leads to greater degradation of topoI. The 
inability of CTDSP1 knockdown cells to dephosphorylate DNA-PKcs and regulate 
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phosphorylation of topoI accelerates the topoI degradation pathway. We also expected to 
see fainter TopoI bands in SN-38 treated conditions. Regarding the control conditions, 
SN-38 treated cells in lane 3 appears somewhat lighter than lane 4. Additionally, SN-38 
treated cells in lane 1 produced a fainter band than lane 1. These results provide further 
evidence that in addition to CTDSP1 knockdown, treatment with SN-38 augments the 
topoI degradation pathway. The magnitude of the actin bands is similar in each lane, 
reflecting that equal concentrations of cell proteins were used in each experimental 
condition.  
Figure 25: Greater degradation of TopoI 
occurs in cells after CTDSP1 knockdown 
and CPT exposure: HCT116 (lanes 1-4) 
were analyzed by immunoblot analysis with 
anti-topoI and anti-β-Actin. Lysates in lanes 1 
and 3 were treated with CPT. Lanes 1 and 2 
demonstrate CTDSP1 knock down conditions. 
The top and bottom bands show levels of 
topoI and actin respectively. 
  
 
 
In order to confirm that knockdown successfully occurred in the siRNA condition 
of the previous experiment, we ran an additional western blot to check for the presence of 
CTDSP1. The production of lighter bands by the latter two lanes in Figure 26 suggests 
that the knockdown of CTDSP1 was successful in these conditions. Therefore, the results 
generated in experiments using these cell lines are reflective of the stated experimental 
conditions. 
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Figure 26: Confirmation of CTDSP1 
knockdown: HCT116 (lanes 1-4) cell 
lysates were analyzed by immunoblot 
analysis with anti-CTDSP1. Lanes 3 
and 4 demonstrate CTDSP1 knock 
down conditions. CTDSP1 is an 
approximately 31.2 Kda protein. 
 
 
 
 
 
 
Immunofluorescent Staining of pDNA-PKcs Results: 
  
 We used immunofluorescent staining to determine whether greater amounts of 
pDNA-PKcs would be observed after knocking down CTDSP1 in HCT116 cells. Figure 
27 shows the amount of pDNA-PKcs after CTDSP1 knockdown with and without SN-38 
treatment. Additionally, figure 27 demonstrates the effects of SN-38 on pDNA-PKcs 
levels in control conditions as well. Similar to the previous immunofluorescence 
experiments, DAPI was used to confirm the presence of cells in each condition by 
staining the nuclear region of cells. The greatest green immunofluorescence is observed 
in the CTDSP1 knockdown condition exposed to SN-38. While null-CTDSP1 cells 
produced moderate levels of immunofluorescence, the effects on pDNA-PKcs were 
intensified when HCT116 cells experienced CTDSP1 knockdown and SN-38 treatment. 
Control cells without SN-38 incubation showed no immunofluorescence, and HCT116 
cells treated with SN-38 showed very small amounts of DNA-PKcs phosphorylation. 
These results suggest that CTDSP1 is involved in CPT resistance via regulation of DNA-
PKcs phosphorylation. In addition, these results show SN-38 treatment increases the rate 
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of DNA-PKcs phosphorylation in both control and CTDSP1 knockdown cells.  However, 
the impact of SN-38 is greatest in cells without CTDSP1.  
Figure 27: α-Rb-
Green 
Immunofluorescent 
stain detecting 
phosphorylated 
DNA-PKcs in both 
control and CTDSP1 
knockdown HCT116 
cells 
 
 
 
Discussion 
 In previous colorectal cancer clinical cases, certain cell lines have proven more 
resistant to CPT chemotherapy treatment than others (Ando et al. 2017). Generating a 
better understanding of the pathway that leads to cellular resistance to CPT may allow 
physicians to identify whether the treatment will be effective in different patients. If 
cellular resistance to CPT can be recognized in a patient before treatment, then patients 
can be provided with an alternative chemotherapy option. In order to establish 
biomarkers of cellular resistance, we examined the topoI degradation pathway involved 
in CPT resistance. The Bharti lab has demonstrated that DNA-PKcs dependent 
phosphorylation of topoI is critical for the CPT induced degradation of topoI. High basal 
levels of topoI s10 phosphorylation ensure CPT resistance in caner cells. We asked if 
DNA-PKcs is regulated by a phosphatase that maintains higher DNA-PKcs activity and 
high basal level of topoI to impart CPT resistance.  The Bharti lab did an siRNA library 
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screen of all nuclear phosphatase to identify the upstream regulator of DNA-PK and have 
identified PTEN and CTDSP1 as two potential regulators of DNA-PK activity. In this 
study we looked at the role of the phosphatase CTDSP1 in the regulation of DNA-PKcs, 
the topoI degradation pathway, and whether CTDSP1 influenced cell survival after CPT 
exposure.  
CTDSP1 Inhibition 
 One of the functions of CTDSP1 is to dephosphorylate the kinase DNA-PKcs 
(Ando et al. 2017). This phosphate removal renders DNA-PKcs inactivated and unable to 
phosphorylate topoI. Phosphorylation of topoI initiates ubiquitination followed by 
degradation of topoI. If topoI is degraded, CPT has no substrate to interact with and is 
unable to destroy cells via topoI inhibition (Ando et al. 2017).   
DNA-PKcs phosphorylation in cell lines HCT116 and HCT15 
 In the first series of experiments, the phosphorylation of DNA-PKcs in two cell 
lines was evaluated using western blots after exposure to CPT and 0µM, 5µM, and 10µM 
concentrations of Rabeprazole. When inhibited, CTDSP1 is unable to remove the 
phosphate from DNA-PKcs, so we expected to observe greater DNA-PKcs 
phosphorylation in cells incubated with larger concentrations of Rabeprazole. The cell 
lines used included sensitive line HCT116 and resistant line HCT15.  When treated with 
CPT, cell line HCT116 is more responsive than HCT15, resulting in greater cell death 
from the HCT116 cell line (Goldwasser et al.1994). The resistance of cell line HCT15 is 
due to enhanced topoI degradation in comparison to cell line HCT116 after treatment 
with CPT.  
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 We wondered if differences between the cell lines would also manifest in DNA-
PKcs phosphorylation when both cell lines experienced CTDSP1 inhibition.  After 
treating cells with 0µM, 5µM, and 10µM concentrations of Rabeprazole for 4 days and 
CPT for 1 hour, we used a western blot to detect the phosphorylation of DNA-PKcs. The 
higher DNA-PKcs phosphorylation was observed in cell line HCT15 treated with both 
CPT and 10µM Rabeprazole. Within the HCT116 cell line conditions, significantly 
higher DNA-PKcs phosphorylation was also exhibited in the 10µM Rabeprazole 
condition. When comparing the two cell lines, the HCT15 cell line produced the most 
prominent bands indicating DNA-PKcs phosphorylation. These results show that 
inhibiting CTDSP1 influences both sensitive and resistant cell lines and results in greater 
DNA-PKcs phosphorylation. The more notable influence of CTDSP1 inhibition in the 
resistant cell line suggests that these cells may already have less functional CTDSP1 or 
some other factor contributing to increased phosphorylation of DNA-PKcs. Additionally, 
these cells may have higher basal levels of DNA-PKcs phosphorylation than sensitive 
cell lines.  Larger amounts of phosphorylated DNA-PKCS in basal conditions may be a 
potential indicator of cellular resistance to CPT. Furthermore, enhanced levels of 
phosphorylated DNA-PKcs caused by inhibition of CTDSP1 in the sensitive HCT116 
cell line may lead to greater resistance of this strain to CPT.   
DNA-PKcs phosphorylation in cell line HCT116  
 We further explored the effects of CTDSP1 inhibition on the sensitive HCT116 
cell line by conducting a western blot measuring phosphorylated DNA-PKcs after 
cellular exposure to 0µM, 5µM, and 10µM concentrations of Rabeprazole. Previous 
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results suggested Rabeprazole treatment leads to increased DNA-PKcs phosphorylation 
and initiation of the topoI degradation pathway in cell line HCT116 after CPT treatment. 
We wanted to see if Rabeprazole would also present cellular effects when cells were not 
exposed to CPT. To determine whether the effects of Rabeprazole were enhanced by CPT 
treatment, we used both HCT116 cells treated with and without CPT. Western blot 
analysis revealed the greatest amount of DNA-PKcs phosphorylation to take place in the 
CPT treated 5µM Rabeprazole condition. We expected to see the stronger band in the 
CPT treated 10µM Rabeprazole condition, but this band was lighter than that of the CPT 
treated 10µM Rabeprazole condition. This result may be due to a lower concentration of 
protein placed into this well, for the actin control band was also smaller at the bottom of 
the blot. However, we also speculated whether 10µM Rabeprazole was a toxic dose 
amount that resulted in cell death.   
 HCT116 cells not exposed to CPT also demonstrated stronger signal in both the 
5µM and 10µM Rabeprazole conditions. The bands were not as pronounced as the band 
produced by cells in the 5µM Rabeprazole and CPT treated condition. The greater DNA-
PKcs phosphorylation observed in CPT treated compared to non-treated cells proposes a 
role of CPT in initiating the cellular resistance topoI degradation pathway. Cellular 
resistance to CPT appears to be two pronged and influenced not only by the presence of 
Rabeprazole, but also by exposure to CPT.  
 Because DNA-PKcs exhibited the greatest amount of phosphorylation in the CPT 
treated 5µM Rabeprazole condition in the last experiment, we conducted another western 
blot only examining the effects of 0µM and 5µM concentrations of Rabeprazole on 
	57 
HCT116 cells treated with and without CPT. The greatest phosphorylation of DNA-PKcs 
occurred in the 5µM CPT treated condition producing the darkest band in the Western 
blot. In the cells without CPT exposure, the DNA-PKcs phosphorylation was greater in 
the 5µM condition compared to the 0µM condition. However, the DNA-PKcs 
phosphorylation of the 5µM Rabeprazole cells treated without CPT was less than the 
DNA-PKcs phosphorylation of 5µM Rabeprazole cells treated with CPT. These results 
further suggest the additive effects of Rabeprazole and CPT treatment combined on 
DNA-PKcs phosphorylation and greater cellular resistance to CPT.  
TopoI levels in cell lines HCT116 and HCT15 
 The previous western blots examining DNA-PKcs phosphorylation revealed 
greater DNA-PKcs phosphorylation after cells were treated with both CPT and 
Rabeprazole. Once phosphorylated, the function of DNA-PKcs is to phosphorylate topoI, 
marking the protein for ubiquitination followed by degradation. Along with the greater 
phosphorylation of DNA-PKcs observed, we also expected to see greater topoI 
degradation after inhibiting CTDSP1. We first produced a western blot evaluating topoI 
levels in resistant cell line HCT15 and sensitive cell line HCT116 after treatment with 
CPT and 0µM, 5µM, and 10µM concentrations of Rabeprazole. Unlike cell line HCT116, 
the HCT15 cell line did not produce a topoI band in any of the Rabeprazole conditions. 
Even when CTDSP1 was not inhibited, cell line HCT15 did not reveal the presence of 
topoI after treatment with CPT. These results support the role of accelerated topoI 
degradation as a contributor to the resistant nature of cell line HCT15 to CPT. In contrast 
to HCT15 cells, the HCT116 cell line produced a topoI band in each Rabeprazole 
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treatment condition. The darkest topoI band was shown in the 0µM Rabeprazole 
condition and the faintest topoI band was observed in the 10µM Rabeprazole condition. 
Greater CTDSP1 inhibition leads to augmented topoI degradation in the sensitive 
HCT116 cell line. From a mechanistic perspective, CTDSP1 appears to inhibit the 
dephosphorylation of DNA-PKcs, allowing phosphorylated DNA-PKcs to phosphorylate 
topoI and promote topoI degradation. After treatment with Rabeprazole, the HCT116 cell 
line shows less topoI and appears more similar to the resistant cell line HCT15. These 
results show the function of the phosphatase CTDSP1 as a regulator of DNA-PKcs 
phosphorylation may be a distinguishing factor between resistant and sensitive cell lines 
to CPT. Additionally, in the 0µM Rabeprazole treatment condition, cell line HCT116 
does produce a dark topoI band and may be vulnerable to treatment with CPT.  
TopoI levels in cell line HCT116  
 In order to determine whether the influence of Rabeprazole on topoisomerase 
levels in HCT116 cells was magnified by treatment with CPT, we conducted a western 
blot solely examining the sensitive cell line. When treated with 0µM and 5µM 
concentrations of Rabeprazole and no CPT, the darkest topoI band was produced with no 
inhibition of CTDSP1 in the 0µM Rabeprazole condition. The topoI band produced is 
characteristic of normal HCT116 cells not observed in HCT15 cells. After treatment with 
a 5µM concentration of Rabeprazole, HCT116 cells produced a fainter topoI band more 
characteristic of a resistant cell line. The decreased topoI present in the 5µM Rabeprazole 
condition provides evidence that CTDPS1 is a negative regulator of the topoI degradation 
pathway.  
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 The latter two wells in the Figure 14 western blot detected the presence of topoI 
in HCT116 cells treated with CPT exposed to 0µM and 5µM Rabeprazole concentrations 
respectively. Both topoI bands were fainter than bands produced by HCT116 cells only 
exposed to different Rabeprazole conditions without CPT treatment. These results further 
support CPT initiates its own resistance pathway by stimulating degradation of its 
substrate. We expected the faintest band to be seen in the CPT treated 5µM Rabeprazole 
condition due to greater CTDSP1 inhibition like we observed in Figure 13. However, 
there was no observable difference between the topoisomerase bands made by CPT 
treated cells exposed to 0µM and 5µM Rabeprazole concentrations. This may be due to 
enhanced DNA concentration in the 5µM Rabeprazole condition, which is observed by a 
larger bottom band in lane 4 of Figure 14 representing actin levels as a control.   
HCT 116 Cell Survival after CTDSP1 Inhibition 
 After looking at the effects of inhibiting CTDSP1 on both phosphorylated DNA-
PKcs and topoI levels in the cell, we performed a clonogenic assay on cell line HCT116 
exposed to both 0µM and 10µM Rabeprazole conditions. Each HCT116 test group was 
treated with 0, 0.5, 1, 2.5, 5.0, and 7.5nM concentrations of CPT. The experiment was 
conducted three times for the different CPT concentrations and comparisons were made 
using averages of results. In the 0µM Rabeprazole HCT116 cells without CTDSP1 
inhibition, the greatest survival fraction of 0.01 was observed in the 0nM CPT condition. 
Cell death increased with higher concentrations of CPT, with the greatest depletion 
occurring in the 7.5 nM CPT condition with an average survival fraction of 7.75E-05. 
The intended function of CPT is to destroy cells by inhibiting topoI (Ando et al. 2017). 
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Therefore, we expected to see sensitive cell line HCT116 experience cell death with 
exposure to increasing concentrations of the chemotherapy treatment. The goal of the 
clonogenic assay was to determine whether inhibition of CTDSP1 would lead to a greater 
average survival fraction of HCT116 cells after treatment with CPT. In the HCT116 cells 
with CTDSP1 inhibited by 10µM concentrations of Rabeprazole, the survival fraction 
was greater in the 0nM compared to the 7.5nM CPT treatment condition with values of 
0.01 and 0.0007 respectively.  
 While the survival fraction of HCT116 cells incubated with both 0µM and 10µM 
Rabeprazole was similar when treated with 0nM CPT, the survival fraction between the 
cell groups differed significantly between the two groups as the concentration of CPT 
was increased.  Figure 15 demonstrates the survival fraction of HCT116 cells treated with 
10µM Rabeprazole is greater than HCT116 cells with no Rabeprazole after subjection to 
each concentration of CPT. The increased survival fraction of HCT116 cells after 
treatment with CPT indicates greater cellular resistance to CPT. This data supports the 
hypothesis that CTDSP1 inhibition in a sensitive cell line leads to cellular resistance to 
CPT. The greatest differences in survival are observed in experimental groups looking at 
0.5nM and 1.0nM concentrations of CPT. At concentrations greater than 1.0nM CPT 
concentrations, there is still greater survival in the group experiencing CTDSP1 
inhibition, but the difference is less drastic.  
 The clonogenic assay demonstrated that when CTDSP1 is inhibited in a sensitive 
cell line like HCT116, the survival fraction of cells exposed to CPT increases. 
Additionally, differences in cell survival were not noticeable in control conditions where 
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cells were not treated with CPT. Previous experiments showed CTDSP1 inhibition leads 
to increased DNA-PKcs phosphorylation and lower levels of topoI in HCT116 cells 
incubated with CPT. The results of these experiments in tandem with the differences in 
survival fractions obtained from the clonogenic assay corroborate stimulation of the topoI 
degradation pathway as the mechanism responsible for cellular resistance to CPT.  
Immunofluorescent Staining of phosphorylated DNA-PKcs in cell line HCT116: 
 In order to visualize the differences in DNA-PKcs phosphorylation in cell line 
HCT116 after inhibition of CTDSP1, we examined one HCT116 cell group treated with 
0µM Rabeprazole and another treated with 10µM Rabeprazole under the microscope after 
staining pDNA-PKcs. We tagged the primary anti pDNA-PKcs antibody with a 
fluorescent α-Rb secondary antibody that would stain any present phosphorylated DNA-
PKcs a fluorescent green. In addition to staining pDNA-PKcs, we also used the DAPI 
stain as a control. Because the fluorescent blue DAPI stain targets A-T regions of DNA, 
we expected all cells to show up as blue under the microscope. The purpose of the DAPI 
stain was to provide information about the amount of cells present in each slide view.  
 The HCT116 cell line treated with 0µM Rabeprazole revealed only a small speck 
of green fluorescence under the microscope despite the many cells present in the frame 
confirmed by the blue fluorescent DAPI stain. Minimal green fluorescence revealed there 
was little DNA-PKcs phosphorylation in cells without CTDSP1 inhibition. The HCT116 
cell line treated with 10µM Rabeprazole showed a much greater amount of green 
fluorescence in comparison to the 0µM Rabeprazole experimental condition. The DAPI 
stain used in Figures 17 and 18 established a similar amount of cells were present in both 
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the 0 and 10µM Rabeprazole experimental frames. This eliminated cell number as a 
confounding factor and differences in DNA-PKcs phosphorylation were attributed to the 
difference in Rabeprazole concentration. Exposure to the larger 10µM amount of 
Rabeprazole led to a greater amount of DNA-PKcs phosphorylation in cells. The greater 
DNA-PKcs phosphorylation appears to be a significant difference between CPT resistant 
and sensitive cell lines that influence cellular levels of topoI. This experiment focused on 
imaging the HCT116 cells, but in the future it would be interesting to determine whether 
Rabeprazole treated HCT116 cells produced results similar to normal HCT15 imaged 
cells.  
EGFP imaging of topoI in cell line HCT116: 
 Greater DNA-PKcs phosphorylation after Rabeprazole treatment determined in 
the previous immunofluorescent staining experiment led us to investigate the next stage 
of the topoI degradation pathway and examine levels of topoI after Rabeprazole 
treatment. We tagged fluorescent EGFP to topoI in order to visualize the difference in 
topoI levels in HCT116 cells after CTDSP1 inhibition. After treating cells with 0µM, 
5µM, and 10µM doses of Rabeprazole, we evaluated the amount of fluorescence in each 
condition in comparison to the image produced by the control DAPI stain. While the 
results from the DAPI stain were consistent in each Rabeprazole condition, we observed 
the lower levels of green fluorescence in the 10µM Rabeprazole condition and a greater 
amount of green fluorescence in the 0µM Rabeprazole condition. Because the degree of 
EGFP fluorescence observed are linked to levels of topoI, these results show as CTDSP1 
inhibition increases, topoI levels decline; supporting the role of CTDSP1 in the 
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topoisomerase degradation pathway. When the functioning of CTDSP1 was limited, more 
topoI was degraded. As a topoI inhibitor, CPT needs to interact with topoI in order to 
disrupt cellular replication and cause cell death. When less topoI is present in the cell, 
CPT has less substrate to interact with and is unable to effectively destroy cells.  By 
treating HCT116 cells with the CTDSP1 inhibitor, the once CPT sensitive cell line may 
become more resistant to CPT. In the future, it may be beneficial to evaluate basal topoI 
levels in comparison to typically CPT sensitive strains in order to determine whether or 
not the chemotherapy treatment will be effective.  If an individual’s cells exhibit lower 
levels of topoI in comparison to the sensitive cell line, an alternative chemotherapy 
treatment would be recommended, sparing the patient from undergoing a painful yet 
ineffective round of chemotherapy treatment.  
CTDSP1 Knockdown  
 The previous experiments produced data suggesting both CTDSP1inhibition and 
SN-38 treatment enhances topoI degradation. Experiments using Rabeprazole showed 
faster topoI degradation conferred greater cellular resistance to SN38. The next set of 
experiments were focused on cell line HCT116 and the HCT116 derivative cell line 12-
G10. Previously the most prominent differences were observed in these sensitive cell 
lines, so we used these cell lines to examine the effects of CTDSP1 knockdown on 
cellular resistance.  The same western blots produced for inhibitor experiments were 
performed for CTDSP1 knockdown experiments. 
DNA-PKcs phosphorylation in cell lines HCT116 and 12-G10: 
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 First, we used a western blot to detect differences in DNA-PKcs phosphorylation 
between cells with and without CTDSP1 knocked down in both cell lines HCT116 and 
12-G10. As discussed earlier, cells without the functional CTDSP1 phosphatase would be 
expected to have greater DNA-PKcs phosphorylation. Previously, we noticed SN-38 
treatment intensified the effects of CTDSP1 knockdown, so we incubated a set of cells in 
both control and knock down conditions with SN-38 for one hour. In Figure 21 we 
noticed darker bands in the CTDSP1 knockdown condition for HCT116 cells relative to 
the controls, suggesting greater DNA-PKcs phosphorylation in the absence of CTDSP1. 
The complete absence of a band in the HCT116 control condition without SN-38 
incubation revealed that SN-38 also influences DNA-PKcs phosphorylation. In contrast, 
when HCT116 control cells were treated with SN-38, a faint band was produced. Even 
without CTDSP1 knockdown. SN-38 appeared to influence the DNA-PKcs 
phosphorylation in cell line HCT-116, once again suggesting that cellular resistance to 
CPT depends on both treatment with the drug and CTDSP1 functionality. Additionally, 
cell line 12-G10 showed differences between CTDSP1 knockdown and control 
conditions. CTDSP1 knockdown cells that were not exposed to CPT produced the darkest 
band, or greatest amount of phosphorylated DNA-PKcs. We expected CTDSP1 
knockdown cells to produce darker bands than control cells, for we saw similar results in 
with greater CTDSP1 inhibition. However, we were surprised that the CTDSP1 
knockdown cells incubated with CPT produced a fainter pDNA-PKcs band than the 
CTDSP1 knockdown cells without CPT. DNA-PKcs phosphorylation is an early step in 
the topoI degradation pathway and previous data suggested SN-38 enhanced the 
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degradation pathway of topoI. However, we also noticed the majority of bands in this 
lane look lighter compared to the other bands on the blot. This suggests there is less 
protein present overall in this lane and may explain the discrepancy. 
 In order to determine whether or not an error had been made with protein 
concentrations in the first western blot, we produced the pDNA-PKcs western blot shown 
in Figure 22. This time the darkest band for both HCT116 and 12-G10 cells was 
produced in the CTDSP1 knockdown and CPT treated condition. Additionally, even 
control conditions showed darker bands after CPT exposure. Greater phosphorylation of 
DNA-PKcs occurs when CTDSP1 is knocked down and cells are treated with CPT. These 
results are consistent with immunofluorescent findings in Figure 27 that show CTDSP1-
knockdown cells demonstrate greater pDNA-PKcs phosphorylation, especially when 
treated with SN-38 compared to control cells. The differences between CTDSP1 
knockdown cells incubated with and without CPT is much more drastic than the 
difference between control cells with and without CPT exposure. This suggests that CPT 
may contribute to greater DNA-PKcs phosphorylation by interfering with CTDSP1 
functionality.  
TopoI levels in cell lines HCT116 and 12-G10: 
 We continued to explore the impact of CTDSP1 knockdown and CPT treatment 
on the topoI degradation pathway by looking at levels of topoI in HCT116 and 12-G10 
cell lines. No significant difference was observed in HCT116 cells. However, 12-G10 
cells did demonstrate differences between the experimental conditions. We expected 
CTDSP1 knockdown cells treated with CPT to produce the faintest topoI band, revealing 
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accelerated degradation that would later translate to greater cellular resistance to CPT. 
The topoI western blot shown in Figure 23 showed the faintest band was produced in the 
CTDSP1 knockdown CPT treated condition. Additionally, we observed a larger actin 
band in the CTDSP1 knockdown CPT treated condition. Since actin was used as a control 
to establish constant protein concentrations, this suggests a greater amount of protein was 
present in this condition. Therefore, if a protein concentration more similar to the other 
lanes were used, the differences may be even more significant that already observed.   
 Because of the inconclusive results produced by cell line HCT116 in the previous 
experiment, we repeated the topoI western blot shown in Figure 25 using only HCT116 
cell line to determine whether or not CTDSP1 knockdown had any influence on topoI 
degradation of these cells. This time, there was a clear difference between cells CTDSP1 
knock down and control conditions. Cells with CTDSP1 knocked down produced much 
lighter topoI bands than cells with normal CTDSP1. Lighter bands demonstrated greater 
topoI degradation. Cells treated with CPT also showed fainter bands than cells in the 
same condition without CPT treatment.  These results contribute more evidence that 
CTDSP1 functionality and CPT play a role in cellular resistance to CPT by enhancing 
topoI degradation.  
Confirmation of CTDSP1 knock down in HCT116 and 12-G10 cell lines: 
 The results produced in the CTDSP1 knockdown experiments mirror those found 
in the Rabeprazole inhibition experiments. Greater CTDSP1 inhibition, as well as 
knockdown of CTDSP1, both lead to greater DNA-PKcs phosphorylation and topoI 
degradation. The effects of both knockdown and inhibition are also magnified by 
	67 
exposure of cells to CPT. To confirm that the knockdown experiments were truly 
indicative of cells without functional CTDSP1, we produced the western blot shown in 
Figure 24. We used a CTDSP1 detecting antibody to determine whether CTDSP1 was 
present in any of the experimental conditions for both cell lines HCT116 and 12-G10. 
The production of large dark bands would indicate the presence of CTDSP1. The results 
revealed four prominent dark bands and the presence of CTDSP1 in the control 
conditions for both HCT1116 and 12-G10 cells. The faint bands in the CTDSP1 
knockdown conditions show knockdown of CTDSP1 did occur. Because CTDSP1 was 
successfully knocked down, we confirmed the data produced accurately portrays the 
experimental conditions indicated.  
Limitations 
 Although findings from each experiment were suggestive of the role of CTDSP1 
inhibition in greater topoI degradation, there were limitations to the study. The maximum 
concentration of Rabeprazole used in any experiment was the small amount of 10µM. We 
refrained from using larger doses of Rabeprazole in order to prevent cells from dying. If 
cells died after treatment, we would be unable to observe differences in amounts of 
phosphorylated DNA-PKcs or topoI. Our experiments are limited to providing 
information about the impact of very small concentrations of Rabeprazole on CPT 
resistance.  
  Additionally, prior literature discusses inhibition of SCP1 family proteins as one 
of the functions of Rabeprazole. However, Rabeprazole is also documented as a proton 
pump inhibitor used for ulcer treatments (Gu et al. 2014).  Currently, there are not many 
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literature investigations of the function of Rabeprazole. It is possible that in addition to 
CDTSP1 inhibition, there are other unknown functions of Rabeprazole that may influence 
the results of these experiments.    
 In the first series of experiments, we used western blots to evaluate the values of 
phosphorylated DNA-PKcs and topoI in cells treated with and without CPT and various 
concentrations of Rabeprazole. 1-hour treatment with 2.5µM CPT remained consistent 
for each experimental condition. The western blot results only represent cellular 
conditions after the 1-hour exposure to CPT. Perhaps longer treatment with CPT would 
make differences observed between the Rabeprazole exposed cell lines moot and 
ultimately destroy all the cells regardless of the amount of functioning CTDSP1.  
 Another caveat of using western blots involves the difficulty of producing a blot 
with limited interference. The topoI detecting blots produced very clear results, but the 
pDNA-PKcs blots were more difficult to read. Identifying the phosphorylated DNA-PKcs 
moiety was more challenging since phosphorylation of many proteins occurs throughout 
the cell. In order to produce a clearer blot, we washed the blot with buffers free of 
phosphate and lengthened the wash period before producing images. We also found the 
Immobilon-P Transfer membrane produced the most distinct pDNA-PKcs western blot 
image.  
 Producing a distinctive blot is not the only challenge of using a western blot to 
gather information. The validity of results depends on the knowledge that the same 
amount of protein was added to each well being compared. For the western blots 
examining topoI, we also used an anti β-actin antibody to confirm that DNA 
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concentrations were similar between each condition. Because the western blots 
examining phosphorylated DNA-PKcs already presented a lot of interference from other 
phosphorylated compounds, we did not use the β-actin control primary antibody. 
Therefore, when running the experiments, both types of western blots were conducted 
using the same concentrations of cell protein, so the β-actin antibody presentation on the 
topoI blot could be used vicariously for the pDNA-PKcs blot to indicate whether 
concentrations used were equivalent. To further ensure that results were accurate, we 
performed each experiment numerous times to ensure consistent data was being 
produced.  
 Similar to the western blot experiments, the clonogenic assay experiment was 
conducted using small concentrations of both CPT and Rabeprazole. Differences in 
pDNA-PKcs and topoI were observed with the small CPT and Rabeprazole 
concentrations in our experiments. Therefore, we think if concentrations of both 
substances were increased, then even greater differences would be observable. However, 
since we did not perform experiments with increased concentrations ourselves, the scope 
of how representative the data produced is of cellular resistance to CPT is limited.  
 The immunofluorescent staining of phosphorylated DNA-PKcs was also 
conducted carefully in order to avoid confounding results. Images under the microscope 
were taken immediately after the 4-hour treatment with Rabeprazole in order to capture 
the most accurate picture of phosphorylated DNA-PKcs. The next step in the topoI 
degradation pathway is phosphorylation of topoI by phosphorylated DNA-PKcs. We 
attempted to capture an image of phosphorylated topoI as well in this immunofluorescent 
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imaging experiment, but we were unsuccessful. The topoI spends a limited time in the 
phosphorylated state before successive degradation. Most topoI had been degraded by the 
time we captured an image. In order to gain more information about the amount of topoI 
levels in the cell, we used the EGFP read out experiment as an alternative.  
 Both the EGFP read out experiment and immunofluorescent phosphorylated 
DNA-PKcs experiment were only conducted on the sensitive cell line HCT116. We also 
only looked at cell line HCT116 exposed to different concentrations of Rabeprazole and 
neglected to treat the cells with CPT. We still do not know whether adding CPT in 
tandem with varying Rabeprazole concentrations as an additional variable would show 
more drastic results. Lastly, no imaging was conducted on the resistant HCT15 cell line, 
so we did not provide visual data allowing the two cell lines to be directly compared.  
Future Experiments 
 In the future, it would be interesting to see the effects of larger concentrations of 
Rabeprazole on the resistance of both cell lines HCT116 and HCT15 to CPT. Further 
comparisons between HCT116 and HCT15 cell lines would also be helpful in 
determining resistant cellular characteristics. In addition to evaluating the cellular levels 
of pDNA-PKcs and topoI, perhaps there are additional morphological differences 
between the sensitive and resistant cell lines. Whether these differences may be able to be 
induced in the sensitive cell line HCT116 would give greater insight to the topoI 
degradation pathway. In addition to comparing cell lines, it would be beneficial to 
compare the CPT resistance of cells with PTEN and CTDSP1 knockdown. Perhaps one 
phosphatase has a greater influence on the topoI pathway than the other, or both 
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phosphatases have a similar effect. To build upon this investigation, it would be 
interesting to see if cellular resistance to CPT was magnified by the knockdown of both 
CTDSP1 and PTEN by conducting the same western blot experiments. Lastly, it would 
be fascinating to work with the HCT15 cell line in order to determine whether cellular 
resistance to CPT is reversible. The ability to both induce and remove cellular resistance 
to CPT via manipulation of the topoI degradation pathway will provide useful 
information for future chemotherapy drug design.  
Applications 
 Understanding the effects of CTDSP1 on the topoI degradation pathway and 
cellular resistance to CPT can be utilized to benefit the patient community plagued by 
colorectal cancer. These experiments have identified high levels of DNA-PKcs 
phosphorylation and low levels of topoI as indicators of cellular resistance to CPT. Our 
research revealed these conditions are augmented by non-functional or inhibited 
CTDSP1, and previous studies have indicated PTEN as a phosphatase that produces 
results analogous to CTDSP1 (Lin et al. 2014). Conditions for these factors can be 
measured in sensitive cell lines to use as a baseline for comparison in a clinical setting. 
When consulting new patients with colorectal cancer, physicians can first take a 
colorectal cancer cell sample and measure basal DNA-PKcs phosphorylation levels 
within the cell, in addition to phosphorylated topoI and topoI. If levels of phosphorylated 
substrates are high, or if the amount of topoI is low, then there is a high likelihood of 
CTP resistance and an Oxialiplatin based treatment should be used instead.  
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 The next step in this line of research is to determine ways to quantify the amount 
of these substrates to make them effective biomarkers. Developing specific antibodies for 
these substrates with a fluorescent tag is one avenue that can be explored in the future. In 
addition to pDNA-PKcs and topoI, researchers may be able to examine the functionality 
of CTDSP1 and PTEN in new patients. Limited activation of these phosphatases also 
suggests a patient will be resistant to CPT treatment. 
 This research takes a positive step in the direction towards personalized medicine. 
Rather than take a chance by putting a patient on a chemotherapy that works better for 
most people, doctors will have the tools to find the best treatment for a specific person. A 
biomarker will give physicians an opportunity to provide a patient with a better 
alternative treatment if there is evidence an individual’s response may deviate from the 
majority. The successful development of a biomarker for colorectal cancer chemotherapy 
treatments may inspire researchers to investigate resistance trends of chemotherapy 
treatments for other cancers. Better understanding of drug effects and resistance patterns 
on different types of people will reduce the amount of issued unsuccessful chemotherapy 
treatments. Ultimately, this line of research has the potential to identify patients that will 
be responsive to medications, so chemotherapy treatments can be catered towards patient-
specific needs.  
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APPENDIX 
Table 1: Dishes of cell lines HCT15 and HCT116 exposed to varying concentrations 
of Rabeprazole 
0µM Rabeprazole   5µM Rabeprazole  10µM Rabeprazole 
Dish 1: HCT15 4E7 Dish 2: HCT15 4E7 Dish 3: HCT 15 4E7 
Dish 4: HCT116 1-2 
G10 
Dish 5: HCT116 1-2 
G10 
Dish 6: HCT116 1-2 
G10 
 
Table 2: Cell Lysate Buffer Contents 
Concentration  Substance 
150 mM NaCl 
50 mM Tris, pH 7.5 
1% NP-40 
1 mM DTT 
1 mM EDTA 
 NaF 
 NaV 
 PMSF 
 Pepstatin 
 Aprotinin 	
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Table 3:Cell Lysate Buffer Contents Adjusted to be used in 10 mL volume 
Concentration  Substance Amount (µL) 
5 M NaCl 300 
1 M Tris, pH 7.5 500 
100% NP-40 100 
1 M DTT 10 
0.5 M EDTA 20 
 NaF 50 
 NaV 50 
 PMSF 50 
 Pepstatin 50 
 Aprotinin 50 
 MilliQ water 8,820 	
 
Table 4: Cell Lysate Preparation of HCT15 and HCT116 cell lines incubated with 
SN38 and various Rabeprazole concentrations 
Tube 
1 
Tube 2 Tube 3 Tube 4 Tube 5 Tube 6 Tube 7 
Lysate 4E57 
HCT15  
+ SN-38 
4E57 
HCT15  
+ SN-38 
4E57 
HCT15  
+ SN-38  
12-G10 
HCT116 
+SN-38  
12-G10 
HCT116 
+ SN-38 
12-G10 
HCT116 
SN-38 
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0µM 
Rabepraz
ole 
5µM 
Rabeprazol
e 
10µM 
Rabeprazol
e 
0µMRabep
razole 
5µM 
Rabepraz
ole 
10µMRabe
prazole 
 
Table 5: Materials used to create 5% gel 
 Separating Stacking 
Water  5.73mL 3mL 
Monomer (brown bottle in 
the fridge) 305 acrylamide 
1.67mL 660µL 
Running buffer and SDS 2.6mL 650 and then 700µL 
APS (10% test tube in 
fridge)  
0.070mL or 70µL 0.070mL or 70µL 
TEMED (Use immediately 
after adding) 
7µL or 0.007mL 12µL 
 
Table 6: Materials used to create a 7.5 percent gel  
 Separating Stacking 
Water 4.9mL 3mL 
Monomer (brown bottle in 
the fridge) 305 acrylamide 
2.5mL 660µL 
Running buffer and SDS 2.6mL 650 and then 700µL 
APS (10% test tube in 
fridge)  
0.070mL or 70µL 0.070mL or 70µL 
TEMED (Use immediately 
after adding) 
7µL or 0.007 mL 12µL 
 
Table 7: Quantity of Sample and Marker added to each Well of the Western Blot gel 
Well Quantity (µL) Substance 
1 5 Marker 
2 20 Sample 
3 20 Sample 
4 20 Sample 
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5 20 Sample 
6 20 Sample 
7 20 Sample 
8 5 Marker 
 
Table 8: 10cm plates of HCT116-1-2G10 cells cultured in different Rabeprazole and 
SN38 Conditions 
Plate 1 0µM Rabeprazole Control 
Plate 2 10µM Rabeprazole  Control 
Plate 3 0µM Rabeprazole +SN-38 
Plate 4 10µM Rabeprazole +SN3-8 
 
Table 9: Contents of the HCT116-1-2G10 6-well plate control with 0µM 
Rabeprazole  
 
 
0nM SN-38 
 
Added 2mL of RPMI with 
no SN-38 
0.5nM SN-38 
 
Added 2mL of a solution of 
10mL of RPMI with 0.5µL 
SN-38  
1.0nM SN-38 
 
Added 2mL of a solution of 
4mL of RPMI with 0.4µL 
SN-38 
2.5nM SN-38 
 
Added 2mL of a solution of 
4mL of RPMI with 1 µL 
SN-38 
5.0nM SN-38 
 
Added 2mL of a solution of 
4mL of RPMI with 2 µL 
SN-38 
7.5 nM SN-38 
 
Added 2mL of a solution of 
4mL of RPMI with 3µL 
SN-38 
 
Table 10: Contents of the HCT116-1-2G10 6-well plate with 10µM Rabeprazole  
0 nMSN-38 
 
Added 2mL of RPMI with 
20 µL Rabeprazole with no 
SN38 
0.5nM SN-38 
 
Added 2mL of a solution of 
10mL of RPMI with 80 µL 
Rabeprazole with 0.5µL 
SN38 
1.0nM SN-38 
 
Added 2mL of a solution of 
4mL of RPMI with 20µL 
Rabeprazole with 0.4µL 
SN38 
2.5nM SN-38 
 
5.0nM SN-38 
 
7.5nM SN-38 
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Added 2mL of a solution of 
4mL of RPMI with 20µL 
Rabeprazole with 1µL 
SN38 
Added 2mL of a solution of 
4mL of RPMI with 20µL 
Rabeprazole with 2µL 
SN38 
Added 7.5 nM SN38 
2mL of a solution of 4mL 
of RPMI with 20µL 
Rabeprazole with 3µL 
SN38 
 
Cell counting data 
 
Table 11: Number of Cells in the 0µM Rabeprazole Control Tubes  
 
Box C0 C.5 C1 C 2.5 C 5 C 7.5  
A 22 12 11 29 18 6 
B 12 17 17 26 10 6 
C 12 17 6 17 6 0 
D 13 11 11 30 5 14 
Average 12.25 14.25 11.25 25.5 9.75 6.5 
 
 
Table 12: Number of Cells in the 10µM Rabeprazole Tubes  
 
 
 R0 R 0.5 R1 R 2.5 R 5 R 7.5  
A 3 13 5 6 8 5 
B 0 7 0 15 8 1 
C 0 12 0 11 4 5 
D 0 17 2 11 0 4 
Average 0.75 12.25 1.75 10.75 5.0 3.5 
 
Table 13: CONTROL: Amount of HCT116 cells in 6 well dishes treated with 0µM 
Rabeprazole 
Dish 1 
0nM SN-38 
Cell amount per/mL:1 
RPMI: 121.5µL 
0nM SN-38 
Cell amount per/mL:1 
RPMI: 121.5µL 
0nM SN-38 
Cell amount per/mL:1 
RPMI: 121.5µL 
0.5nM SN-38 
Cell amount per/mL:1 
RPMI: 141.5µL 
0.5nM SN-38 
Cell amount per/mL:1 
RPMI: 141.5µL 
0.5nM SN-38 
Cell amount per/mL:1 
RPMI: 141.5µL 
 
Dish 2 
1nM SN-38 
Cell amount per/mL:1 
1nM SN-38 
Cell amount per/mL:1 
1nM SN-38 
Cell amount per/mL:1 
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RPMI: 111.5µL RPMI: 111.5µL RPMI: 111.5µL 
2.5nM SN-38 
Cell amount per/mL:1 
RPMI: 254µL 
2.5nM SN-38 
Cell amount per/mL:1 
RPMI: 254µL 
2.5nM SN-38 
Cell amount per/mL:1 
RPMI: 254µL 
 
Dish 3 
5nM SN-38 
Cell amount per/mL:1 
RPMI: 96.5µL 
5nM SN-38 
Cell amount per/mL:1 
RPMI: 96.5µL 
5nM SN-38 
Cell amount per/mL:1 
RPMI: 96.5µL 
7.5nM SN-38 
Cell amount per/mL:1 
RPMI: 65µL 
7.5nM SN-38 
Cell amount per/mL:1 
RPMI: 65µL 
7.5nM SN-38 
Cell amount per/mL:1 
RPMI: 65µL 
 
 
Table 14: Amount of HCT116 cells in 6-well dishes treated with 10µM Rabeprazole  
 
Dish 4 
0nM SN-38 
Cell amount per/mL:4 
RPMI: 26µL 
0nM SN-38 
Cell amount per/mL:4 
RPMI: 26µL 
0nM SN-38 
Cell amount per/mL:4 
RPMI: 26µL 
0.5nM SN-38 
Cell amount per/mL:1 
RPMI: 121.5µL 
0.5nM SN-38 
Cell amount per/mL:1 
RPMI: 121.5µL 
0.5nM SN-38 
Cell amount per/mL:1 
RPMI: 121.5µL 
 
Dish 5 
1nM SN-38 
Cell amount per/mL:1 
RPMI: 16.5µL 
1nM SN-38 
Cell amount per/mL:1 
RPMI: 16.5µL 
1nM SN-38 
Cell amount per/mL:1 
RPMI: 16.5µL 
2.5nM SN-38 
Cell amount per/mL:1 
RPMI: 196.5µL 
2.5nM SN-38 
Cell amount per/mL:1 
RPMI: 106.5µL 
2.5nM SN-38 
Cell amount per/mL:1 
RPMI: 106.5µL 
 
Dish 6 
5nM SN-38 
Cell amount per/mL:1 
RPMI: 49µL 
5nM SN-38 
Cell amount per/mL:1 
RPMI: 49µL 
5nM SN-38 
Cell amount per/mL:1 
RPMI: 49µL 
7.5nM SN-38 
Cell amount per/mL:1 
RPMI: 34µL 
7.5nM SN-38 
Cell amount per/mL:1 
RPMI: 34µL 
7.5nM SN-38 
Cell amount per/mL:1 
RPMI: 34µL 
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Table 15:  6-well dish contents of HCT116 cells exposed to 0µM and 10µM 
Rabeprazole Conditions 
Control HCT116 cells 0µM 
Rabeprazole 
Control HCT116 cells 0µM 
Rabeprazole 
Empty 
HCT 116 cells 10µM 
Rabeprazole 
HCT116 cells 10µM 
Rabeprazole 
Empty 
 
Table 16: siRNA Resuspension Volumes and Concentrations 
 
siRNA Amount (nmol) 1xsiRNA Buffer to be added 
(µL) for desired final 
concentration  
 
100µM Stock 
1xsiRNA Buffer to be added 
(µL) for desired final 
concentration  
 
20µM Stock 
5.0 50 250 
 
Table 17: Cell line HCT116 6-well Dish  
Control +SN-38 siRNA +SN-38 Empty 
Control siRNA Empty 
 
Table 18: Cell line 12-G10 6-well Dish  
Control +SN-38 siRNA +SN-38 Empty 
Control siRNA Empty 
 
Table 19: Cell Lysate Preparation of HCT116 and 12-G10 cell lines with and 
without functional CTDSP1 
 
 
Tube 1  
 
Tube 2 
 
Tube 3 
 
Tube 4 
 
Tube 5 
 
Tube 6 
 
Tube 7 
 
Tube 8 
 
HCT116 
control 
-SN-38 
HCT116 
control 
+SN-38 
HCT116 
+siRNA 
-SN-38 
HCT116 
+siRNA 
+SN-38 
12-G10 
control 
-SN-38 
12-G10 
control 
+SN-38 
12-G10 
+siRNA 
-SN-38 
12-G10 
+siRNA 
+SN-38 
 
Table 20: Materials used to create 10% gel 
 Separating Stacking 
Water  5.73mL 3mL 
Monomer (brown bottle in 1.67mL 660µL 
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the fridge) 305 acrylamide 
Running buffer and SDS 2.6mL 650 and then 700µL 
APS (10% test tube in 
fridge)  
0.070mL or 70µL 0.070mL or 70µL 
TEMED (Use immediately 
after adding) 
7µL or 0.007mL 12µL 
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